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One of the ten greatest public health achievements of the 20th century is the 
control of infectious diseases from vaccination according to the Centers for Disease 
Control and prevention (CDC).  It is recommended by the CDC and the Advisory 
Committee on Immunization Practices (ACIP) that everyone 6 months and older 
should receive an annual influenza vaccination.  The influenza vaccine is a safe and 
effective way to prevent the influenza infection and subsequent complications, which 
is particularly important in children because it has been shown to reduce influenza 
illness in older adults.  Currently, the United States utilizes the National Immunization 
Survey (NIS-Flu) to provide estimates of annual vaccination rates of children, which 
are subject to limitations of survey data such as low response and recall bias. 
As of 2009, pharmacists were considered approved influenza vaccinators in all 
states.  Pharmacist-administered vaccination improves access to care through 
increased convenience with proximity, longer hours, and without the need for an 
appointment.  Pharmacists have the authority to vaccinate children against influenza 
and other vaccine preventable diseases based on different authorization models; 
protocols, minimum age restrictions, and/or prescription requirements by state.  The 
utilization of pharmacists as pediatric vaccinators, as well as the implications of the 
restrictions, is not well understood. 
Particularly relevant during the current coronavirus disease 2019 (COVID-19) 
pandemic, pharmacists will have a more substantial role in the vaccination of children.  
In August 2020, the United States Health and Human Services Department (HHS) 




(FDA) authorized vaccine to children 3 years of age and older under the “Third 
Amendment to Declaration Under the Public Readiness and Emergency Preparedness 
Act for Medical Countermeasures Against COVID–19” (PREP Act), which overrides 
state-level regulatory mandates.  Pharmacists are being recognized as well-positioned 
to expand access to all childhood vaccinations in an effort to combat the alarming 
decline in all routine pediatric vaccines observed during the onset of the pandemic due 
to decreased pediatric physician visits and changes in access to healthcare. 
This dissertation provides information that can help to understand the trends in 
utilization of pharmacist-administered pediatric influenza vaccine prior to the PREP 
Act, as well as determine demographic and clinical characteristics predictive of 
utilization of a pharmacy setting for receiving influenza immunizations and determine 
if state-level pediatric vaccination rates by a pharmacist impact state level-influenza 
diagnoses.  For all studies, Optum’s de-identified Clinformatics® Data Mart Database, 
a claims data warehouse of commercially insured persons, was used. 
 In the first manuscript, titled Pharmacist-administered influenza vaccination in 
children and corresponding regulations, a summary of pharmacist immunization 
authorization models allowing pharmacist-administered influenza immunization by 
state from the American Pharmacists Association (APhA) and the National Alliance of 
State Pharmacy Associations (NASPA) was prepared along with a retrospective 
descriptive epidemiology study to analyze trends of pediatric influenza vaccination by 
provider setting using Joinpoint regression.  There are three main models under which 
pharmacists can administer vaccinations: prescription from physician provider, 




prescription nor protocol required).  A vaccination protocol specifies which vaccines 
can be administered under the protocol and vaccine administration procedures, 
including age limitations, usually agreed upon between state-level pharmacist groups, 
state-level physician groups, and the state public health department, without the need 
for a prescription.  In an independent authority model, pharmacists have authority to 
administer vaccines without a prescription or protocol.  Regardless of pharmacist 
authorization models, the minimum age requirements allowing pharmacists to 
vaccinate against influenza vary by state.  There are 14 states with multiple models 
authorizing pharmacist administration of vaccination to children, which commonly 
allow children of any age to be immunized by a pharmacist with a prescription, and 
after a specified age, the protocol/independent authority model becomes effective and 
a prescription is no longer necessary.  In our retrospective cohort, almost 4 million 
pediatric influenza vaccinations were identified from 2010-2017.  The majority took 
place in a pediatrician’s office, 87.7%; followed by a pharmacy, 3.2; convenience care, 
2.3%; emergency care, 0.8%; and other locations, 6.0%.  Pharmacist-administered 
pediatric influenza vaccination was more commonly observed in older children, and 
less common in the Northeast, where there are more restrictive authorization models.  
The utilization trend of pharmacist-administered pediatric influenza vaccination was 
increasing significantly by 19.2% each year over the study period, and the utilization 
trend of influenza immunization within a pediatrician’s office was slightly decreasing 
by 0.9% each year during the same time. 
In the second manuscript, titled Pediatric influenza vaccination rates lower than 




Data Mart Database were compared to the findings reported by the NIS-Flu survey 
estimates from 2010-2017.  Recognizing the limitations of survey data, such as use of 
random-digit-dialed landline and cellular telephone numbers to conduct surveys, 
response bias from low response rates, recall bias, and known overestimations of 
vaccination coverage estimates, we sought to describe pediatric influenza vaccination 
coverage and trends over time using a retrospective cohort study, descriptive statistics,  
and Joinpoint regression.  Current Procedural Terminology, 4th Edition (CPT®) 
procedure codes from a commercially insured pediatric population from 2010 to 2017 
were captured to build the study population.  Over these seven influenza seasons, our 
study population had an average annual pediatric influenza vaccination coverage of 
33.4%, compared to NIS-Flu reported vaccination coverage estimates of 56.5% during 
the same period (p-value <0.0001), resulting in a 51.4% difference between the 
commercially insured pediatric study population and the NIS-Flu estimate.  
Vaccination coverage was highest in children 6 months-4-years old at 52.6% (versus 
68.8% NIS-Flu, p-value <0.0001), and lowest in children 13-17-years old at 20.1% 
(versus 42.8% NIS-Flu, p-value <0.0001). Vaccination coverage over time remained 
stable in the study population (average annual percent change 1.8%, 95% confidence 
interval [CI] -2.3% to 6.0%, p>0.05) versus significantly increasing by 2.8% in NIS-
Flu (95% CI 0.3% to 5.3%, p<0.05).  The results from this study validates the need for 
more accurate vaccination coverage surveillance.  In addition, effective interventions 
are needed to increase pediatric influenza vaccination rates to the Healthy People 2020 




In the third manuscript, titled Demographic and clinical predictors of pharmacist-
administered pediatric influenza immunization, multivariate logistic regression was 
used to determine demographic and clinical characteristics that are predictive to 
receiving influenza immunization in a pharmacy setting compared with influenza 
vaccination in pediatricians’ offices using CPT codes in Optum from the 2016-2017 
influenza season.  Our study found 336,841 children received influenza vaccines by a 
pharmacist (5.2%) and 94.8% of influenza vaccines administered in pediatricians’ 
offices (94.8%).  The following predictors of pharmacist-administered influenza 
vaccination were identified: older age of 13-17 years old (odds ratio [OR], 91.51; 95% 
confidence interval [CI], 73.49-113.94; reference group 6 months to 4 year) and 5-12 
years old (OR, 35.41; 95% CI, 28.45-44.07), states with more lenient age restrictions 
governing pharmacist-administered influenza vaccination of no age restrictions (OR, 
26.68; 95% CI, 21.31-33.41; reference group did not allow pharmacist-administered 
pediatric influenza vaccination in children under 18 years old) and minimum age 2-4 
years old (OR, 33.76; 95% CI, 26.466-43.07), minimum age 5-12 years old and any 
age with prescription (OR, 20.93; 95% CI, 16.75-26.16),  minimum age 5-12 years old 
(OR, 15.54; 95% CI, 12.43-19.43),  minimum age 13-17 years old and any age with 
prescription (OR, 13.62; 95% CI, 10.67-17.39), and minimum age 13-17 years old 
(OR, 8.95; 95% CI, 6.93-11.55), previous year’s influenza vaccination taking place in 
locations of a pharmacy (OR, 22.18; 95% CI, 21.02-23.41; reference group did not 
receive influenza vaccine in the year prior), convenience care (OR, 4.15; 95% CI, 
3.76-7.58), emergency care (OR, 1.69; 95% CI, 1.33-2.14), and other (OR, 1.13; 95% 




reference Northeast), Midwest (OR, 1.60; 95% CI, 1.45-1.77), and West (OR, 1.38; 
95% CI, 1.24-1.55), and routine health examination or follow up appointment in the 6-
month baseline period (OR, 1.59; 95% CI, 1.53-1.65).  Alternatively, the following 
were predictive of pediatricians’ office pediatric influenza vaccination: previous 
diagnosis of acute upper respiratory infection (OR, 0.91; 95% CI, 0.83-0.99); 
attention-deficit/hyperactivity disorder (ADHD) (OR, 0.90; 95% CI, 0.83-0.98); strep 
sore throat (OR, 0.87; 95% CI, 0.79-0.96); cough (OR, 0.85; 95% CI, 0.77-0.94); fever 
(OR, 0.85; 95% CI, 0.76-0.95); obesity (OR, 0.84; 95% CI, 0.73-0.98); otitis media 
(OR, 0.79; 95% CI, 0.70-0.89);  and severe developmental delay (OR, 0.66; 95% CI, 
0.53-0.83).  The strongest drivers of pharmacist-administered pediatric influenza 
vaccination were older age, more lenient minimum age restrictions, and previous 
influenza vaccination in a pharmacy, which is particularly important during the 
COVID-19 pandemic, where pharmacists are likely to be more involved in vaccinating 
children, which may result in sustained changes in pediatric vaccination practices. 
In the fourth and final manuscript, titled Increased proportions of state-level 
pediatric pharmacist-administered influenza immunization decrease influenza 
diagnoses, the proportion of children vaccinated against influenza by pharmacists and 
the proportion diagnosed with influenza were aggregated at the state-level during the 
2016-2017 influenza season, along with potential confounders. The association 
between state-level pediatric pharmacist-administered influenza vaccination and 
influenza diagnoses was assessed using backward manual stepwise beta regression.  
The proportion of children that received an influenza vaccine in a pharmacy varied 




decrease by 6.2% (p=0.0369) per every additional 1% of children vaccinated by a 
pharmacist, after controlling for potential confounding factors.  Fewer influenza 
diagnoses were observed in states with higher pharmacist-administered pediatric 
influenza vaccination. Decreasing influenza diagnoses can help decrease the 
significant burden of influenza in children and throughout communities.  Additionally, 
now that pharmacists have been granted expanded authority to vaccination children 
due to the COVID-19 pandemic, pharmacists play a key role as vaccine providers and 
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This dissertation is written in the Manuscript Format based on the guideline 
provided by the University of Rhode Island Graduate School. A total of four 
manuscripts were prepared that encompass pharmacist-administered pediatric 
influenza vaccination utilization and corresponding regulations (manuscript I), 
pediatric influenza vaccination rates (manuscript II), demographic and clinical 
predictors of pharmacist-administered pediatric influenza immunization (manuscript 
III) and the impact of state-level pharmacist-administered influenza vaccination rates 
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Pharmacist-administered influenza vaccination in children and corresponding 
regulations 
 
Article Summary: While only 3.2% of the 3,937,376 pediatric influenza vaccinations 
from 2010-2017 were pharmacist-administered in a claims database, pharmacist-
administration increased significantly by 19.2% per year. 
What’s Known on This Subject: Pharmacists are authorized to administer vaccines 
to children in the US under state-governed Pharmacist-Authorization models, 
however, minimum age requirements, vaccination protocols, and/or prescription 
requirements may limit pharmacist-administered pediatric vaccination.  There are 
limited published estimates of pharmacist-administered pediatric influenza 
vaccination.  
What This Study Adds: From 2010-2017, only 3.2% of the 3,937,376 pediatric 
influenza vaccination claims from a claims database were administered by a 
pharmacist, which increased significantly by 19.2% each year and were more common 
in older children and in states with fewer restrictions.   
 








Background and Objectives: Though pharmacists are vaccine providers in the 
United States, individual state regulatory mandates, including minimum age, 
vaccination protocols, and/or prescription requirements may limit pharmacist-
administered pediatric vaccination.  Therefore, the purpose of our study was to 
evaluate pharmacist-administered pediatric influenza vaccination rates in a claims 
database and corresponding state-level pharmacist pediatric vaccination authorization 
models. 
Methods: Our retrospective cohort study assessed provider setting for influenza 
vaccination procedure codes among children in Optum’s de-identified Clinformatics® 
Data Mart Database from 2010-2017. State-level pharmacist-administered pediatric 
influenza vaccination and corresponding regulations were assessed, as were time 
trends using Joinpoint regression.   
Results: Of the 3,937,376 pediatric influenza vaccinations identified over the study 
period, only 3.2% were pharmacist-administered (87.7% pediatrician offices, 2.3% 
convenience care clinics, 0.8% emergency care, and 6.0% other locations).  
Pharmacist-administered pediatric influenza vaccination was more commonly 
observed in older children (mean age 12.65 ± 3.26 years).  Pharmacist-administered 
influenza vaccination increased significantly by 19.2% annually over the study period 
(95% confidence interval 9.2%-30.2%, p<0.05).  The Northeast, with more restrictive 
authorization models, represented only 2.2% (n=2,816) of all pharmacist-administered 




Conclusions: Though pharmacist-administered pediatric influenza vaccination is 
permitted in all states, utilization remains low.  Providing children with greater access 
to vaccination with less restrictions could help increase overall vaccination rates.  Due 
to the COVID-19 pandemic and the Public Readiness and Emergency Preparedness 
Act, pharmacists will play a major role in vaccinating children, and future research 
should evaluate uptake of pharmacist-administered pediatric vaccination, including 





Although annual influenza vaccine is recommended by the Centers for Disease 
Control and Prevention (CDC) and the Advisory Committee on Immunization 
Practices (ACIP) for children 6 months and older (1-6), there is continued hesitancy 
towards influenza vaccination (7).  The CDC has consistently reported pediatric 
vaccination rates that are lower than the Healthy People 2020 target of 70% for 
children aged 6 months through 17 years (8, 9), potentially due to barriers in access 
(10).  According to the National Immunization Survey (NIS), a national telephone 
survey conducted by the CDC to assess vaccination coverage among children (6 
months through 17 years) (11), pediatric influenza vaccination rates over the past 
decade have increased from 51.0% in 2010-2011 to 63.8% in 2019-2020 (12). 
While vaccines are often administered in primary care or pediatricians’ offices 
by medical personnel, under the supervision of a physician, pharmacists have been 
approved to administer influenza vaccines to adults in all 50 states since 2009 (13).  
However, regulations enabling pharmacist-administered vaccination also carry 
restrictions for children, such as state-specific minimum age requirements and other 
regulatory limitations, including restricted lists of allowed vaccinations under these 
mandates (14-16).  Vaccination outside of pediatricians’ offices improves vaccine 
access through increased convenience, with expanded hours and without the need for 
an appointment (16).  Additionally, 93% of patients live within five miles of a 
pharmacy and most patients have positive experiences with their pharmacy (17, 18).   
To date, there are limited published estimates of pharmacist-administered 




reported for 5.5% of pediatric influenza vaccinations in the 2017-2018 flu season 
(66.8% doctor’s offices, 16.2% clinics and health centers, 4.3% hospitals, 3.8% 
schools. 1.9% health departments, and 1.5% other settings) (19).  Due to the 
limitations of NIS-Flu, including overestimation of pediatric influenza vaccination and 
other biases due to the nature of survey methods (11), it is unclear whether these 
estimates of pharmacist-administered vaccination are accurate.  Further, state-level 
variations in pharmacist-administered pediatric influenza vaccination remain 
unknown, as does the influence of state-level pharmacist vaccination authorization 
models.  
 As such, the objective of this study was to evaluate state-level pharmacist-
administered pediatric influenza vaccination authorization models alongside state-
level pharmacist-administered pediatric influenza vaccination rates and time trends 















We assessed the distribution of vaccine providers among vaccinated children 
using a health claims database with enrollees from all 50 states and the District of 
Columbia, Optum’s de-identified Clinformatics® Data Mart Database.  Using a 
retrospective cohort study design, we evaluated pediatric influenza vaccinations by 
vaccine provider setting and corresponding variations in patient characteristics.  The 
study population included children with an influenza vaccination record between July 
1, 2010 to June 30, 2017 identified from Current Procedural Terminology, 4th Edition 
(CPT®) procedure codes found in Supplementary Table 1 and under 18 years of age at 
the time of the influenza vaccination claim.  Vaccinations were assigned to influenza 
seasons, where time was divided into 12-month periods from July 1 through June 30 
of the following year (20).  For each season, pediatric patients with full continuous 
enrollment for the 12 months of that season and with at least one influenza CPT® 
code, were for selected for inclusion (20).  Only the first influenza vaccination within 
a season was included, while patients with missing year of birth, state, or sex were 
excluded.   
Vaccine provider setting was categorized as pediatricians’ offices, which 
included family medicine and primary care settings, pharmacist-administered, 
convenience care clinic, emergency care, and other, which included locations such as 
schools or other immunization centers.  Of note, pharmacy-based vaccination did not 
include healthcare clinics located in retail pharmacies (e.g. CVS MinuteClinic) as 
those were categorized under convenience care.  Within each vaccine provider setting, 




authorization minimum age restriction.  Both mean and median age were assessed, as 
well as distribution by age groups per the NIS-Flu categorization of 6-23 months, 2-4 
years, 5-12 years, and 13-17 years (19).  States were grouped into regions per the 2010 
United States Census Bureau of Regions and Division categorizations (21) as regional 
vaccination coverage can vary (22).  We assessed the distribution of influenza vaccine 
provider setting among vaccinated children, and calculated pharmacist-administered 
pediatric influenza vaccination rates for each state (the proportion of vaccinated 
children with pharmacy provider setting within each state).   
A grey literature search was performed to identify state-level regulations 
regarding pharmacist-authority to administer influenza vaccines to children.  Grey 
literature search methods consisted of a Google search of key terms, including 
“pharmacist administered pediatric influenza vaccination” and “minimum age 
restrictions”.  Search results were assessed for state-level regulations.  One document 
was selected for inclusion after full-text review, authored by the American 
Pharmacists Association (APhA) and the National Alliance of State Pharmacy 
Associations (NASPA), due to the corresponding timeframe of the document and the 
study data (14).  Minimum age restrictions were assessed for all authorization models 
within each state.  Pharmacist-administered pediatric influenza vaccination rates were 
then averaged among states with corresponding authorization models and minimum 
age requirements. 
Statistical Analysis 
Demographic characteristics of vaccinated children in each provider setting 




Wilcoxon rank sum test as appropriate in SAS (version 9.4, SAS Institute Inc., Cary, 
NC).  Time trends in pediatric vaccination were assessed by vaccination provider 
setting, and stratified by age, with Joinpoint regression, over the seven vaccination 
seasons with each season being an equally weighted interval.  Average annual percent 
change (AAPC) and corresponding 95% confidence intervals by vaccination provider 
setting were calculated using the Joinpoint Regression Program, version 4.7.0.0 


















Pharmacist-administered pediatric influenza vaccination rates 
Our study included 3,937,376 influenza vaccinations among children over 
seven influenza seasons, from 2010 to 2017 (Table 1).  Of the total influenza 
vaccinations, most occurred in pediatricians’ offices (87.7%, n=3,451,658), followed 
by pharmacist-administered (3.2%, n=125,709), convenience care (2.3%, n=90,304), 
and emergency care (0.8%, n=32,499). 
Mean and median ages (Table 1 and Figure 1) were highest among those 
vaccinated by a pharmacist (mean age 12.7 ± 3.3 years), followed by convenience care 
(mean 9.7 ± 4.2 years), other locations (mean 8.4 ± 4.9 years), emergency care (mean 
8.2 ± 4.6 years), and youngest among those vaccinated in pediatricians’ offices (mean 
7.0 ± 4.8 years).  Within the pharmacy setting, 56.3% (n=70,806) of influenza 
vaccinations were among children 13-17-year-old age group.  In comparison, only 
16.9% (n=582,152) of children that were vaccinated in a pediatrician’s office were 13-
17 years old.   
Compared to the pediatricians’ office setting, the distribution of pediatric 
influenza vaccinations by sex differed significantly for the pharmacy (p=0.004) and 
convenience care (p<0.0001) settings.  Influenza immunization of males was 
marginally higher than females in all settings including the pharmacy, except for 
convenience care.   
Statistically significant differences were observed in the distribution of 
geographic region when comparing pediatrician's office to the other vaccine provider 




office setting (39.5%),  pharmacy (45.0%), and convenience care (53.0%), whereas 
most vaccinations in emergency care (50.0%) and other settings (36.7%) occurred in 
the West.  Of all pharmacist-administered pediatric influenza vaccinations, only 2.2% 
(n=2,816) occurred in the Northeast, as Connecticut, Massachusetts, New York, and 
Vermont do not allow pharmacist-administered pediatric influenza vaccination.   
Over the study period, the average annual percent change in pharmacist-
administered pediatric influenza vaccination increased significantly by 19.2% (95% CI 
9.2 to 30.2, p<0.05), from 1.5% in the 2010-2011 season to 4.2% in the 2016-2017 
season (Figure 2). During the same period, the average annual percent change in 
pediatric influenza vaccination in pediatricians’ office decreased significantly by 0.9% 
(95% CI -1.3 to -0.5, p<0.05).  A separate analysis was performed comparing 
influenza vaccination coverage trends from pediatricians’ offices and pharmacies, 
stratified by age group, over the same period (Figure 3).  For all age groups (6 months 
to 4 years, 5 to 12 years, and 13 to 17 years), there was a significant decreasing trend 
in utilization of pediatricians’ offices as influenza vaccination providers; 6 months to 4 
year old AAPC -0.3% (95% CI -0.5% to -0.2%, p<0.05), 5 to 12 year old AAPC -
1.0% (95% CI -1.2% to -0.7%, p<0.05), and 13 to 17 year old AAPC -1.5% (95% CI -
2.7% to -0.4%, p<0.05).  The average annual percent change in pharmacist-
administered pediatric influenza vaccination increased significantly in the 5 to 12 
years old age group by 17.12% (95% CI 8.6 to 26.3, p<0.05) and the 13 to 17 year old 
age group by 15.2% (95% CI 6.5 to 24.6, p<0.05).  The average annual percent change 




old age group also showed an increasing trend by 2.5% (95% CI -10.6 to 17.5, 
p>0.05), however, non-significant. 
Pharmacist-administered pediatric influenza vaccination authorization models  
There are three main models under which pharmacists can administer 
vaccinations (Table 2): prescription from physician provider, vaccination protocol, or 
pharmacist independent authority.  A prescription from a provider is handled on a 
case-by-case basis.  A vaccination protocol covers all children within the state and 
specifies which vaccines can be administered under the protocol and vaccine 
administration procedures, including age limitations, usually agreed upon between 
state-level pharmacist groups, state-level physician groups, and the state public health 
department.  Under a vaccination protocol, no prescription is required.  In an 
independent authority model, pharmacists have the authority to prescribe and 
administer the vaccine to the child without a protocol or physician prescription (23).  
Some states follow multiple models, which commonly allow children at a specified 
age to be vaccinated by a pharmacist under a protocol/independent authority, and 
children below the minimum age restriction require a prescription (14, 23). 
Regardless of pharmacist authorization models (Table 2), the minimum age 
requirements allowing pharmacists to vaccinate against influenza vary by state (Figure 
4).  Arizona, where pharmacists are authorized to administer influenza vaccinations 
under two authorization models, the least restrictive being pharmacists’ independent 
authority beginning at 3 years of age, had the highest percent of children vaccinated by 
a pharmacist at 7.8%.  Following Arizona were states where there is no age limit; New 




(5.9%), Michigan (5.5%), and Nebraska (5.0%).  The pharmacist-administered 
influenza vaccination rate in Texas was 5.6%, which allows pharmacist-administered 
influenza vaccination for children 7 years and older under a protocol and at any age 
with a prescription.  Hawaii had the lowest pharmacist-administered influenza 
vaccination (0.1%), as the mandate only allows pharmacist-administered influenza 
vaccination in children 14 years and older with a physician prescription.  As of July 
2016 (14), six states did not allow pharmacist-administered influenza vaccination for 
children of any age under 18, which included Connecticut, Florida, Massachusetts, 


















To our knowledge, this is the first study to evaluate pharmacy-based 
immunization rates among a commercially insured pediatric population in the United 
States.  Our study found that over seven influenza seasons from 2010-2017, only 3.2% 
of all influenza vaccinations occurred in a pharmacy setting and the majority of 
pediatric influenza vaccinations were found to be administered in pediatricians’ 
offices, 87.7%.  However, also during this time, administration of pediatric influenza 
vaccines by pharmacists increased significantly by 19.2% each year.  We observed a 
slight but significant decrease over time in influenza vaccinations in pediatricians’ 
offices across all age groups, and a larger increase in vaccinations by pharmacists.  A 
potential explanation is that pharmacist-administered influenza vaccination offers 
vaccination access to children who may not have otherwise been vaccinated from their 
pediatrician and is helping to increase overall pediatric influenza vaccination rates. 
Pharmacist-administered influenza vaccination was more common among 
older children and where administration laws allow have less restrictive age 
limitations around pharmacist-administered pediatric vaccination.  States with more 
restrictions and older minimum age requirements, had lower rates of pharmacist-
administered influenza immunization.   
According to NIS-Flu data for the 2017-2018 influenza season, 5.5% of all 
children ages 6 months to 17 years old were immunized in a pharmacy setting, and 
66.8% of children were vaccinated in their doctor’s office (19), while 28.3% of adults 
were vaccinated in a pharmacy and 34.7% in physicians’ offices (24).  NIS-Flu is a 




of households.  This self-reported survey data is subject to recall bias and non-
response bias from low response rates (11).  The findings presented from our cohort 
study were from claims data from a commercially insured population with records of 
actual influenza vaccine administrations by provider setting and are not subject to 
survey data biases. 
As also reported by NIS-Flu data, influenza vaccine setting varied by age 
group in our findings; for example children less than 5 years old utilized pediatricians’ 
offices more frequently than other settings and children 13-17 years old utilized a 
pharmacy setting more frequently (19).  As children get older, they are less likely to 
receive the influenza vaccine, which has been a consistent trend observed by NIS-Flu 
since 2010 (19).  For example, in the 2015-2016 influenza season, NIS-Flu 
vaccination coverage estimates within age groups were as follows; 6 months-23 
months 75.3%, 2-4 years 66.8%, 5-12 years 61.8%, and 13-17 years 46.8% (24).  This 
may be due to a decrease in the number of physician visits as children get older.   
Administration of annual influenza vaccine typically occurs around the same time 
every year, in late fall or early winter, which may not align with a child’s annual 
routine examination.  A pharmacy can satisfy increased interest in vaccination outside 
of a pediatrician’s office. 
A main objective of pharmacist-administered influenza immunization is to 
expand access to vaccination through increased accessibility, convenience, extended 
hours, and widespread locations (8) for patients who find it difficult to reach 
traditional healthcare services, which could in turn increase vaccination coverage for 




available on weekends and holidays.  A study from the 2011-2012 influenza season 
estimated that over 30% of all adult vaccinations administered at a Walgreens 
pharmacy chain were during evenings, weekends, or holidays (25).  Another important 
role pharmacists play is through vaccine advocacy (26).  Pharmacists were more 
successful than traditional healthcare providers in administering vaccines to patients 
that were not current in their immunizations after performing an immunization needs 
assessment in adults (8).  However, it can be more costly and less efficient when 
pharmacists require a prescription from a healthcare provider to administer vaccines to 
children (23). 
Increasing influenza vaccination among children is critical to controlling 
influenza outbreaks.  It has been found that vaccinating children, in addition to 
protecting other children, protects the entire community by limiting the transmission 
of the virus, in particular to vulnerable populations such as the elderly and 
immunocompromised (27).  Expansion of the ability for pharmacists to administer 
vaccines and increase vaccination rates among children, for influenza and other 
epidemics, is critical for public health. 
As of August 2020, pharmacists in all states have been authorized by the U.S. 
Health and Human Services Department (HHS) to administer any FDA authorized 
vaccines to children aged 3 to 18 under the “Third Amendment to Declaration Under 
the Public Readiness and Emergency Preparedness Act for Medical Countermeasures 
Against COVID–19” (PREP Act) for the duration of the COVID-19 pandemic (28).  
Due to the current COVID-19 pandemic, there has been an alarming decline in routine 




healthcare access (such as closed offices or limited hours, and corresponding increases 
in virtual visits) (28, 29).  Data collected from the Vaccines for Children program, a 
national program that provides vaccines to approximately 50% of children in the 
United States (29), showed that physicians participating in the program ordered 
approximately 2.5 million fewer non-influenza routine vaccines and 250,000 less 
measles-containing vaccines, and the decline was more prominent in children 2-18 
years old (29, 30).  In the declaration, pharmacists are recognized as being well 
positioned to expand access to all childhood vaccinations, which can help combat the 
public health threat of declining vaccination rates (28). 
As this amendment is recent and parents may not be aware of this change, it is 
unclear to what extent parents will elect to have their children vaccinated by a 
pharmacist.  Future efforts should monitor uptake of pharmacist-administered 
pediatric vaccination to determine utilization rates, and whether increased vaccination 
by pharmacists compensates for reductions in pediatrician’s office vaccinations.  It is 
possible that societal vaccination practices may shift as a result of this expansion in 
care, similar to changes observed in satisfaction with and therefore preference in some 
cases for virtual healthcare (31).  It remains unknown how long pharmacist-
administered vaccination authorization will remain under the PREP Act.  Studying its 
long-term impacts will be important for advocacy efforts of continued expanded 
access to vaccination for children in the United States at their local pharmacies, 
particularly if pharmacists become the primary vaccine provider for pediatric COVID-





The population studied here was limited to pediatric patients from one claims 
database within the United States, compiled from vaccination procedure codes.  As 
such, our study did not assess influenza vaccination by provider setting among 
pediatric patients with Medicaid, which is estimated to include approximately 30 
million children nationally, or other private health plans (32), and distributions by 
vaccine provider may vary in these populations.  Missing from our cohort are 
influenza vaccinations that were not processed through health insurance, such as 
through free public health clinics.  Due to the nature of the database, age was 
calculated using the date of vaccination and the patient’s year of birth.  In patients that 
are vaccinated in early fall and have birthdays occurring later in the year, the patient 
would be considered one year older if they were vaccinated before their birthday.  The 
study relies on the accuracy and consistency of provider categorization in the source 
data to indicate vaccine administration setting.  Vaccinations in other locations, 
including non-specific locations were uncommon, encompassing 6.0% of pediatric 
influenza vaccination in our study population.  Another major limitation of our study 
was that the study database did not include race, and therefore we could not assess 
trends in vaccination setting by race or ethnicity.  It is important that future research 
evaluate vaccination setting by race and ethnicity, as this may provide insight into 
vaccination disparities and opportunities to develop interventions to improve influenza 
vaccination rates in children. Additionally, we could not assess parent willingness 
(33), access to care, socioeconomic status, and education (7) which may also influence 




Overall pediatric influenza vaccination rates vary by state (19), as did the 
proportion of children within this dataset of the total state pediatric population, which 
we did not assess in this study.  Pharmacist authorization models were assessed as of 
July 2016, and therefore changes in authorization models may have occurred over the 
7-year period when pediatric influenza vaccination claims were assessed.  Lastly, due 
to the large population size, some statistically significant differences were observed 




















Although pharmacist-administered influenza vaccination has been allowed in 
all 50 states for over 10 years (13), various state-level restrictions on pharmacist-
administered pediatric influenza vaccination, such as protocols, prescription 
requirements, and minimum age restrictions, impact uptake of pharmacist-
administered pediatric influenza vaccination.  Of the nearly 4 million, pediatric 
influenza vaccinations included in our study, only 3.2% were pharmacist-
administered.  We found that annually, utilization of pharmacists as influenza 
vaccinators of children increased significantly by 19.2% each year over the 7-year 
study period.  Providing children with greater access to vaccinations with less 
restrictions could help increase influenza vaccination rates to get closer to the Healthy 
People 2020 target of at least 70% for children (9).  Additionally, during the current 
COVID-19 pandemic, pharmacists will be instrumental for overcoming the profound 
decrease in all pediatric vaccination rates observed during the pandemic (28).  Future 
research should evaluate uptake of pharmacist-administered pediatric vaccination for 
influenza, other childhood vaccines, and pediatric COVID-19 vaccination when it 
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1.8 TABLES AND FIGURES 





Care Emergency Care Other 
n = 3,451,658 
(87.7%) 
n = 125,709 
(3.2%) 
n = 90,304  
(2.3%) 
n = 32,499  
(0.8%) 
n = 237,206 
(6.0%) 
Age (Mean ± SD) 7.04 ± 4.81 12.65 ± 3.26* 9.73 ± 4.23* 8.21 ± 4.64* 8.37 ± 4.90* 
Age Group†      
    6 months - 2 years 768,750 (22.3%) 87 (0.1%)* 2,784 (3.1%)* 4,092 (12.6%)* 35,227 (14.9%)* 
    2 - 4 years 520,856 (15.1%) 1,314 (1.1%)* 8,775 (9.7%)* 4,221 (13.0%)* 28,300 (11.9%)* 
    5 - 12 years 1,579,900 (45.8%) 53,502 (42.6%)* 51,919 (57.5%)* 17,178 (52.9%)* 115,465 (48.7%)* 
    13 - 17 years 582,152 (16.9%) 70,806 (56.3%)* 26,826 (29.7%)* 7,008 (21.6%)* 58,214 (24.5%)* 
Sex†      
     Female 1,687,410 (48.9%) 62,095 (49.4%)* 45,513 (50.4%)* 15,959 (49.1%) 116,650 (49.2%)* 





Region†      
     Midwest1 969,480 (28.1%) 28,548 (22.7%)* 24,134 (26.7%)* 6,178 (19.0%)* 82,370 (34.7%)* 
     Northeast2 486,435 (14.1%) 2,816 (2.2%)* 6,934 (7.7%)* 1,775 (5.5%)* 17,536 (7.4%)* 
     South3 1,361,550 (39.5%) 56,517 (45.0%)* 47,898 (53.0%)* 8,288 (25.5%)* 50,333 (21.2%)* 
     West4 634,193 (18.4%) 37,828 (30.1%)* 11,338 (12.6%)* 16,258 (50.0%)* 86,967 (36.7%)* 
State-Level Pharmacist Authorization Model, Age Restrictions†    
     No age restriction 822121 (23.8%) 46238 (36.8%)* 14429 (16.0%)* 17369 (53.4%)* 94696 (39.9%)* 
     Min age 2-4 years old 80514 (2.3%) 7509 (6.0%)* 4899 (5.4%)* 85 (0.3%)* 3119 (1.3%)* 
     Min age 5-12 years old, 
          Any age with Rx 
784427 (22.7%) 39765 (31.6%)* 21981 (24.3%)* 3477 (10.7%)* 33708 (14.2%)* 
     Min age 5-12 years old 1031281 (29.9%) 22207 (17.7%)* 23692 (26.2%)* 7701 (23.7%)* 79558 (33.5%)* 
     Min age 13-17 years old,  
          Any age with Rx 
175394 (5.1%) 6099 (4.9%)* 8103 (9.0%)* 863 (2.7%)* 10549 (4.5%)* 
     Min age 13-17 years old5 103572 (3.0%) 2652 (2.1%)* 5086 (5.6%)* 363 (1.1%)* 3003 (1.3%)* 





† No. (%) 
* P <0.05 
Demographic characteristics of vaccinated children in each provider setting were compared with the pediatricians’ office setting using 
chi-square tests (age group, sex region, state-level pharmacist authorization model age restrictions) and Wilcoxon rank sum test (age). 
 
1 Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota, South Dakota, Nebraska, Kansas 
2 Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania 
3 West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland, Delaware, Tennessee, South Carolina, Georgia, 
Florida, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, Texas 
4 Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, Alaska, Hawaii, New Mexico, Arizona 




Table 2. Pharmacist-administered pediatric influenza vaccination authorization 
























































































10 Illinois 3.3% 





District of Columbia2,3 
Missouri2,3 
2.2% 
13 Georgia2,3 3.0% 
14 North Carolina 2.3% 
Prescription3 
Any Age 













6 New Jersey1,3 0.9% 
14 Hawaii 0.1% 
 
Note: Pharmacist-administered pediatric influenza vaccination authorization models as of July 
2016 [14].  Models are not mutually exclusive for each state, as states may have different 
authorization models for different age groups.  14 states use multiple models authorizing 
pharmacist administered vaccination of children.  Commonly prescriptions are used to allow 
children of any age to be vaccinated by a pharmacist, and then after a specified age, the 
protocol/independent authority model takes over and a prescription is no longer needed. 
 
*Influenza vaccine is recommended in children 6 months of age and older. 
1 Pharmacists have authority to administer vaccines without a protocol or prescription. 
2 Vaccination protocol specifies vaccine administration procedures usually agreed upon 
between state-level pharmacist and physician groups and the state public health department. 








Figure 1. Median age of pediatric influenza vaccination by vaccine provider setting  
 
 
Figure 1. Median ages for the pediatric influenza vaccination settings are shown as the center 
bar, the box represents the third quartile (Q3) through the first quartile (Q1), and the range of 
the data from maximum to minimum are shown in the vertical lines  Age significantly differed 
among all pediatric vaccination providers when compared to pediatricians’ offices using the 

















Note: AAPC, average annual percent change; CI, confidence interval.  The Joinpoint Regression Program was used to calculate average annual 
percent change (AAPC) and 95% CI.  *Significant trend at P<0.05.  Refer to left y-axis for influenza vaccination in pediatricians’ offices.  Refer to 
right y-axis for all other influenza vaccine provider settings. 
Pediatrician (AAPC -0.9%, 95% CI -1.3% to -0.5%)* 
Pharmacy (AAPC 19.2%, 95% CI 9.2% to 30.2%)* 
Convenience Care (AAPC 4.8%, 95% CI -1.5% to 11.6%) 
Emergency Care (AAPC 8.9%, 95% CI -2.4% to 21.6%) 





Figure 3. Trends in pediatric influenza vaccination by vaccine provider setting and age group, 2010-2017 
 
 
Note: AAPC, average annual percent change; CI, confidence interval.  The Joinpoint Regression Program was used to calculate average annual 
percent change (AAPC) and 95% CI.  *Significant trend at P<0.05.  Refer to left y-axis for influenza vaccination in pediatricians’ offices and right 
y-axis for pharmacy. 
6 months to 4 years; Pediatrician (AAPC -0.3%*, 95% CI -0.5% to -0.2%)  Pharmacy (AAPC 2.5%, 95% CI -10.6% to 17.5%) 
5 to 12 years;  Pediatrician (AAPC -1.0%*, 95% CI -1.2% to -0.7%)  Pharmacy (AAPC 17.1%*, 95% CI 8.6% to 26.3%) 





Figure 4. Pharmacist-administered pediatric influenza vaccination minimum age restrictions (as of July 2016) and pharmacist-
administered influenza vaccination rates by state, 2010-2017 
 






Pediatric influenza vaccination rates lower than previous estimates in the United 
States 
 
Article Summary: The average annual influenza vaccination coverage was 51.4% 
lower in our study population of commercially insured children compared to estimates 
reported by NIS-Flu from 2010-2017. 
What’s Known on This Subject: Currently, estimates of influenza vaccination 
coverage among children in the United States are determined from national surveys.  
Survey study designs have known limitations such as recall bias and response bias, 
resulting in recognized overestimated influenza vaccination coverage estimates.  
What This Study Adds: From 2010-2017, significant differences in the average 
annual pediatric influenza vaccination coverage were observed between NIS-Flu 
survey data and vaccination claim records.  More accurate vaccination coverage 
surveillance is needed, along with interventions to increase pediatric influenza 
vaccination rates. 
 






Background:  Annually, pediatric influenza vaccination coverage estimates are 
ascertained from health surveys, such as the National Immunization Survey (NIS-Flu). 
From 2010-2017, vaccination coverage among children ranged from 51-59%.  
Recognizing the limitations of national health survey data, we sought to describe 
temporal trends in pediatric influenza vaccination coverage, and demographic 
differences among a commercially insured large national cohort from 07/01/2010-
06/30/2017. 
Methods: Influenza vaccination coverage was assessed among children (<18 years) 
with continuous enrollment in the de-identified Optum Clinformatics® Data Mart 
Database, and from NIS-Flu. Time trends in vaccination coverage were assessed using 
Joinpoint regression, overall and stratified by age group, sex, and geographic region. 
Results: The average annual pediatric influenza vaccination coverage was 33.4% in 
our study population versus 56.5% reported from NIS-Flu during the same period (p-
value <0.0001). Vaccination coverage was highest in children 6 months-4-years old at 
52.6% (versus 68.8% NIS-Flu, p-value <0.0001), and lowest in the 13-17-year old age 
group at 20.1% (versus 42.8% NIS-Flu, p-value <0.0001). Vaccination coverage over 
time remained stable in our study population (average annual percent change 1.8%, 
95% confidence interval [CI] -2.3% to 6.0%) versus significantly increasing by 2.8% 
in NIS-Flu (95% CI 0.3% to 5.3%). 
Conclusions:  Vaccination coverage in our commercially insured pediatric population 
was 51.4% lower than estimates from NIS-Flu during the same period, suggesting the 




in future COVID-19 vaccination efforts.  Effective interventions are needed to 






The primary prevention and control of the influenza virus is through 
vaccination (1) and the seasonal influenza vaccination program is one of the most 
commonly utilized immunization programs in the United States (U.S.) (2).  The 
influenza vaccine is safe and effective, prevents influenza-related complications (3, 4), 
and it is particularly important in children as vaccination among children has been 
shown to reduce influenza illness in older adults (5).   
Although annual influenza vaccination is recommended for children, there is 
continued hesitancy towards flu vaccines (6-8), and vaccination rates against influenza 
remain below the Healthy People 2020 Goals of 70% for children aged 6 months 
through 17 years of age (9).  During the 2016-2017 influenza season, the National 
Health Interview Survey (NHIS) and National Immunization Survey (NIS) vaccination 
coverage among children was 49.7% (9) and 59.0% (10) respectively, and in 2014, a 
Health Center Patient Survey estimated influenza vaccination coverage among 
children to be 67.8% (11).   
Actual annual influenza vaccine coverage in the United States, particularly 
among children, is not well described as influenza vaccination coverage estimates are 
ascertained from national surveys rather than vaccination records (12).  Other 
countries, such as France, estimate influenza vaccine coverage based on the number of 
influenza vaccines that were submitted for reimbursement (13).  As such, estimates of 
annual influenza vaccination coverage in the U.S. have important limitations due to 
the nature of the survey design.  Each year, the Centers for Disease Control and 




and stratified by age group, gender, and state based on findings from the NIS-Flu (10, 
12).  The NIS-Flu collects data from October through the following June from all 50 
states and the District of Columbia (D.C.) via national dual landline and cellular list-
assisted random-digit-dialed telephone survey of households (12).  Response rates are 
approximately 50.8% to 53.1% for landline phones, and 26.2% to 28.7% for cellular 
phones (12).  Influenza vaccination coverage is then estimated with Kaplan-Meier 
survival analysis to determine cumulative vaccination coverage by state, estimated 
from the state’s total monthly population by age (12).   
Non-response bias may influence the accuracy of the estimates.  In addition to 
non-response bias, which can remain after weighting adjustments, this survey data is 
also subject to recall bias (12).  As a result of these limitations, it is recognized that 
estimates from the NIS-Flu are “certainly” overestimated, since in previous years, the 
estimated coverage exceeded the number of vaccines distributed by approximately 4 to 
5 million in the 2009-2010 influenza season (12, 14).  A previous study using 
Medicare fee-for-service administrative claims database found influenza vaccination 
coverage estimates for the 2015-2016 influenza season to be 51% for adults 65 years 
and older and 32% for adults under 65 years of age (15), whereas, the Behavioral Risk 
Factor Surveillance System (BRFSS) estimates reported by the CDC were 63.4% for 
adults 65 years and older and 36.3% for adults 18-64 years of age (16).  Vaccination 
coverage estimates from NIS-Flu have also been higher than estimates from the 
National Health Interview Survey (NHIS) (10).   
Therefore, the objective of this study was to quantify influenza vaccination 




population.  Further we sought to compare coverage rates from our study population 
with estimates from NIS-Flu, overall and by state, and to assess temporal trends in 
























This retrospective cohort study included pediatric patients less than (<) 18 
years of age in Optum’s de-identified Clinformatics® Data Mart Database, a claims 
data warehouse of commercially insured persons.  Time was assessed as annual 
influenza seasons, from July 1 through June 30 of the following year (17), from 2010 
to 2017.  To be included in an influenza season, continuous enrollment was required 
for the entire timeframe of each season.  For example, to be included in the 2016-2017 
season, children had to be continuously enrolled from July 1, 2016 through June 30, 
2017.  Age was calculated for each season, using the patient’s year of birth and year 
from the beginning of the specific season.  For example, 2016 was used in the 
calculation of age for the 2016-2017 influenza season.  Among children with 
continuous enrollment each season, the proportion vaccinated during that season was 
identified based on the presence of an influenza vaccination Current Procedural 
Terminology, 4th Edition (CPT®-4) code, which can be found in Supplementary Table 
1.   
Only the initial influenza vaccination record during each season was included, 
as it is recommended to be vaccinated once per season, with the exception of initial 
influenza vaccine given to children 6 months to 8 years old, where two vaccines are 
recommended in the first season (17).  Patients with missing age, sex, or state were 
excluded from the study.  Coverage rates were calculated by age group, sex, and 
geographic region (18).  In order to compare coverage rates from the Optum 




states and the District of Columbia and age was categorized as 6 months-4 years, 5-12 
years, and 13-17 years (12).  Vaccination coverage by state was also assessed (10).   
Statistical Analysis 
To compare influenza vaccination coverage from the claims database with 
previous national estimates, pediatric influenza vaccination coverage data from the 
NIS-Flu for the same time period was included (12).  Student’s t-test was used to 
compare pediatric influenza vaccination coverage between the study population and 
NIS-Flu.  For visual state-level comparisons between the study population and NIS-
Flu, the 2016-2017 season was utilized, as it was the most recent available, and the 
2017-2018 season from NIS-Flu was utilized, as it was the first season NIS began 
reporting state-level pediatric vaccination coverage (10).  All statistical analyses were 
performed using SAS (version 9.4, SAS Institute Inc., Cary, NC). 
Joinpoint regression (19) was utilized to assess trends in influenza vaccination 
coverage over seven influenza vaccination seasons, from 2010 to 2017.  Each season 
was considered an interval and all intervals were equally weighted.  Using permutation 
tests, the trend data is fit into the simplest Joinpoint model and the average annual 
percent changes (AAPC) in vaccination coverage was calculated and expressed as a 
proportion of the population vaccinated overall, and stratified by age, sex, and region. 
AAPCs and corresponding 95% confidence intervals were calculated using the 
Joinpoint Regression Program, version 4.7.0.0 (National Cancer Institute, Bethesda, 







In the study population of children from all 50 states and D.C., with per season 
continuous enrollment in the de-identified Optum Clinformatics® Data Mart 
Database, an average of 562,482 (± 32,961) children were vaccinated each season.  
Average annual pediatric influenza vaccination coverage was 33.4% (± 2.4%; Table 
1), ranging from 29.7% in the 2010-2011 season to a peak of 36.3% during the 2013-
2014 season, where the predominant virus strain was influenza A (H1N1), and ending 
at 34.1% in 2016-2017 season (Figure 1) (20).  When compared to the same seven 
influenza seasons, the estimated annual pediatric influenza vaccination coverage of 
56.5% from the NIS-Flu differed significantly from our study population (p-value 
<0.0001), starting at 51.0% in the 2010-2011 season, to a peak of 59.3% during the 
2014-2015 and 2015-2016 seasons, and ending at 59.0% in 2016-2017 season (12), 
resulting in a 51.4% difference between the commercially insured pediatric study 
population and the NIS-Flu estimate. 
Influenza vaccination coverage among children in our study remained stable 
over the study period (AAPC 1.8%, 95% CI, -2.3% to 6.0%, p-value >0.05), while 
NIS-Flu estimates showed a statistically significant increase in pediatric vaccination 
coverage (AAPC 2.8%, 95% CI 0.3% to 5.3%, p-value <0.05; Table 1 and Figure 1).  
This significant increase in pediatric vaccination coverage was observed in all age 
groups in the NIS-Flu, while vaccination coverage remained relatively stable in all age 
groups in the study population.  The average annual percent change in vaccination 
coverage was highest for the 13-17-year age group in the study population, at 6.0% 




Flu, though non-significant in the study population (NIS-Flu AAPC 6.6%, 95% CI, 
2.8% to 10.5%, p-value <0.05). 
In our study population, no significant temporal trends were observed in 
pediatric influenza vaccination by sex or region (Table 1 and Figure 2).  Average 
annual influenza vaccination coverage among children was highest in the Northeast 
(45.2%), followed by the Midwest (34.8%), South (31.3%), and lowest in the West 
(30.3%).  The average annual percent change in pediatric influenza vaccination 
coverage was highest in the South (AAPC 2.6%, 95% CI -1.1% to 6.4%), and lowest 
in the Midwest (AAPC 1.0%, 95% CI -2.8% to 4.9%), however all were not 
statistically significant.  Average annual pediatric influenza vaccination coverage was 
33.4% for girls and 33.3% for boys (p-value = 0.98) (Table 1).  The average annual 
percent change in pediatric influenza vaccination coverage was 1.8% per year (95% 
CI, -2.1% to 5.7%) for girls and 1.7% per year (95% CI, -2.2% to 5.9%) for boys. 
Among our commercially insured pediatric study population during the 2016-
2017 influenza season, the highest state-level pediatric influenza vaccination coverage 
was 52.6% in Rhode Island and the lowest was 14.1% in Alaska (Figure 3).  Rhode 
Island also had the highest estimated influenza vaccination coverage according to NIS-
Flu during the 2017-2018 influenza season (10), however, with a higher estimated 
vaccination rate of 76.2%.  The average state-level difference in influenza vaccination 
coverage between our study and NIS-Flu was 25.1%.  Utah had the smallest difference 
in influenza vaccination coverage estimates of 12.8% between our study and NIS-Flu 





Among a large national cohort of commercially insured children, average 
pediatric influenza vaccination coverage was 33.4% per year, which is less than half of 
the Healthy People 2020 target of 70% (9), and 51.4% lower than coverage estimates 
of 56.5% from the NIS-Flu survey during the same time period (p-value <0.0001) 
(12).  According to NIS-Flu, pediatric influenza vaccination coverage increased 
significantly by 2.8% each year over the 7-year period, while in the Optum 
Clinformatics® Data Mart, coverage increased non-significantly by 1.8%. Similar to 
previous studies, this study found that vaccination coverage was highest among 
younger children and decreased with increasing age (10, 12, 16, 21). 
Pediatric influenza vaccination coverage rates in our study population were 
consistently lower than the vaccination coverage estimates reported by NIS-Flu (10, 
12), across age groups and states.  NIS-Flu is subject to non-response bias from low 
response rates among other biases related to the survey design, weighting, and 
estimation (10, 12, 22-25).  The large discrepancies between estimates from our study 
population and the NIS-Flu reported estimates are likely attributable to the recognized 
over-estimation of influenza vaccination coverage by NIS-Flu, as their estimates have 
previously exceeded the number of seasonal influenza vaccines distributed (12, 14).  
These observed differences between records of vaccine administrations in our study 
population and survey responses from NIS-Flu suggest that survey data may not 
accurately estimate vaccination coverage.  In future research, it would be interesting to 
see whether vaccination coverage from other publicly and privately insured children 




population.  Further, it may be informative to compare NIS-Flu estimates for adults, 
also captured using survey data, to claims data from other insured adult populations. 
The low pediatric influenza vaccination coverage rate observed in our study is 
extremely concerning and interventions are critically needed to increase pediatric 
influenza immunization in order to control future influenzas epidemics.  Strategies that 
have been shown to increase vaccination rates among children, such as decreasing 
practice-related barriers and increasing access to vaccines, as well as patient/parent 
education, recommendations, and reminders, need to be expanded (26).  Children are 
well-known for transmitting influenza throughout their homes and communities (27), 
and vaccination among children has been shown to decrease influenza-related 
hospitalizations in older adults (5).  Although annual influenza vaccination is included 
in the recommended immunization schedule for children by the Advisory Committee 
on Immunization Practices (ACIP), influenza vaccination rates among children are 
much lower than other childhood vaccines (28).  This may be attributed to vaccine 
hesitancy due to potential concerns about side effects, misconceptions regarding 
immunizations being associated with autism, objections to the number of 
immunizations administered in childhood, moral or religious concerns, lack of access, 
and lack of information (28).  Additionally, concerns regarding vaccine effectiveness, 
which varies by season, are thought to contribute to increased influenza vaccine 
hesitancy, compared with other vaccines (29). 
Lower-than-expected pediatric influenza vaccination coverage is particularly 
alarming during the current Coronavirus Disease 2019 (COVID-19) pandemic.  The 




influenza vaccine has been well-studied, with an excellent safety profile which is well-
understood based on decades of scientific research and experience.  Conversely, 
COVID-19 vaccines are new, along with the virus and presentation of illness 
themselves (31).  COVID-19 vaccines have not been studied for decades, like 
influenza, which may impact COVID-19 vaccination hesitancy among children and 
parents. 
These findings demonstrate an urgent public health need to improve influenza 
vaccination uptake and better understand influenza vaccine hesitancy, as well as 
COVID-19 vaccine hesitancy.  Rates of influenza infection have decreased over the 
2020-2021 influenza season compared to previous seasons (32), which can likely be 
attributed to COVID-19 risk mitigation practices such as masking, handwashing, 
social distancing, virtual learning, among other changes in health behaviors and 
infection control practices (33).  As COVID-19 vaccinations are made widely 
available, risk mitigation practices may wane, and the impacts of concurrent influenza 
and COVID-19 outbreaks are not yet understood, highlighting the urgent need for the 
development of effective interventions to increase influenza vaccination, as well as 
COVID-19 vaccination in children.  Herd immunity against COVID-19 can only be 
created through widespread vaccination (6).  If the low influenza vaccination coverage 
rates observed in this study are representative of future COVID-19 vaccination 
coverage rates, when COVID-19 vaccines become authorized for use in children, 
addressing parents’ hesitancy towards vaccination will be “instrumental to achieving 




With expectations that influenza and COVID-19 will both circulate 
concurrently in the future and require annual vaccination to address changes in virus 
variants, a combination quadrivalent seasonal influenza and COVID-19 vaccine from 
Novovax, Inc using recombinant hemagglutinin (HA) nanoparticle technology is 
currently in development (35).  Tracking the differences in vaccination uptake from a 
combination vaccine compared to individual vaccines may become an important 
strategy to help increase vaccine uptake for both viruses.  Furthermore, greater 
understanding of the origin around vaccine hesitancy, can be used to develop 
strategies to inform such undecided individuals and in turn increase vaccination rates, 
particularly for the influenza and COVID-19 vaccines (36). 
Limitations 
A claims database was utilized for this study and we measured influenza 
vaccination coverage from influenza vaccination procedure code claims.  Therefore, 
influenza vaccinations that were not submitted for reimbursement, such as those 
administered through free public health clinics which did not process the vaccination 
through health insurance, were not captured.  This underestimation is expected to be 
low, assuming the majority of vaccine administrations are processed through health 
insurance among a commercially insured pediatric population.  However, we were 
unable to obtain an accurate published estimate of this figure.  It should also be noted 
that the 5-12-year age group encompasses eight years, while the other age groups 
encompass five or less years, however, these age groupings were used to easily 
compare findings from our study population to NIS-Flu data.  The population studied 




United States with enrollees from all 50 states and D.C., and did not include pediatric 
patients with Medicaid, which is estimated to include approximately 30 million 
children nationally (37), or other private health plans.  The proportion of children who 
were vaccinated and included in the study population varied by state, as did the total 
state pediatric population enrolled in the database.  Therefore, estimates from our 
study population are not state-wide estimates.  Other variables which may influence 
influenza vaccination coverage including socioeconomic status, and education (29), 
comorbidities, religion, parent/family vaccination rates, geographic issues of access, 
and parental perceptions  of susceptibility to influenza virus and vaccine risk (38) were 
not assessed. 
A major limitation of our study was that race and ethnicity were not available 
in our dataset, and therefore we were unable to assess trends in vaccination coverage 
by race and ethnicity.  Influenza vaccination coverage estimates by race from NIS-Flu 
in 2017 were as follows 55.8% White, 55.4% Black, 61.7% Hispanic, 62.0% non-
Hispanic, 68.8% Asian, 53.8% American Indian or Alaska Native, and 57.3% other 
races (10).  We would expect the observed overestimation of NIS-Flu estimates for 
other variables to hold true for race and ethnicities, although it is unclear as to whether 










The primary and most cost-effective way to prevent influenza illness is through 
vaccination (27), which has been licensed in the United States for over 75 years (30).  
The vaccine is well-studied and has been proven to be safe and effective in countless 
studies.  Despite the extensive experience with influenza vaccination in children, 
annual vaccination coverage was found to be only 33.4% over seven influenza seasons 
from 2010-2017 among a large national cohort of commercially insured children from 
all 50 states and D.C.  Vaccination coverage in the study population was 51.4% lower 
than the average annual influenza vaccination coverage estimate of 56.5% (12) 
reported by NIS-Flu from survey data, for the same period.  
The significantly higher coverage rate reported by NIS-Flu suggests the need 
for more accurate estimates of pediatric influenza vaccination coverage.  Newer 
surveillance techniques, designed to accurately estimate influenza vaccination 
coverage, may also have direct applications to the COVID-19 pandemic and future 
pandemics with respect to vaccination coverage and distribution.  Most importantly, 
interventions are critically needed to increase pediatric influenza vaccination rates.  
Similar efforts will be needed to ensure high utilization of pediatric COVID-19 
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2.8 TABLES AND FIGURES 
Table 1. Trends in annual pediatric influenza vaccination coverage, Optum 
Clinformatics® Data Mart and NIS-Flu 





 (95% confidence 
interval) 
Overall 




1.8 (-2.3 – 6.0) 
NIS-Flu 56.5% 2.8* (0.3 – 5.3) 
Age Group   
Optum Clinformatics® Data Mart,  
6 months to 4 years 
52.6% -0.0 (-1.8 – 1.8) 
NIS-Flu, 6 months to 4 years 68.8% 1.6* (1.4 – 1.8) 
Optum Clinformatics® Data Mart,  
5 to 12 years 
33.2% 1.9 (-2.3 – 6.3) 
NIS-Flu, 5 to 12 years 58.9% 2.1* (0.4 – 3.9) 
Optum Clinformatics® Data Mart,  
13 to 17 years 
20.1% 6.0 (0.0 – 12.5) 
NIS-Flu, 13 to 17 years 42.8% 6.6* (2.8 – 10.5) 
Sex, Optum Clinformatics® Data Mart  
Female 33.4% 1.8 (-2.1 – 5.7) 





Region, Optum Clinformatics® Data Mart 
Northeast1 45.1% 1.3 (-1.0 – 3.7) 
Midwest2 34.8% 1.0 (-2.8 – 4.9) 
South3 31.3% 2.6 (-1.1 – 6.4) 
West4 30.3% 2.0 (-1.8 – 5.9) 
 
NIS-Flu = National Immunization Survey-Flu 
* P-value <0.05 
 
1 Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, 
New Jersey, Pennsylvania 
2 Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota, 
South Dakota, Nebraska, Kansas 
3 West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland, 
Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas, 
Louisiana, Oklahoma, Texas 
4 Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, 











Figure 1. Annual pediatric influenza vaccination coverage by age group, Optum Clinformatics® Data Mart and NIS-Flu 
 
 
Solid line = Optum Clinformatics® Data Mart. 
Dotted line = National Immunization Survey-Flu.  





Figure 2. Annual pediatric influenza vaccination coverage by region, Optum Clinformatics® Data Mart 
 
 
Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, Pennsylvania 
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota, South Dakota, Nebraska, Kansas 
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland, Delaware, Tennessee, South Carolina, Georgia, 
Florida, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, Texas 




















• Older age was a driver of pharmacist-administered pediatric influenza 
vaccination 
• Minimum age restrictions act as a barrier to pharmacist-administered 
vaccination  
• Utilization of pharmacists as flu vaccinators was driven by previous experience  
• Pharmacists may have a greater role in pediatric vaccination due to the PREP 
Act 
• Pediatric vaccination practices may change because of this recent expansion 
 







Background: Pediatricians’ offices are primary locations for pediatric influenza 
vaccination.  However, pharmacists are well-positioned as immunizers, particularly in 
light of the COVID-19 pandemic and Public Readiness and Emergency Preparedness 
(PREP) Act which has expanded the authority of pharmacists to vaccinate children. 
Methods: We used the de-identified Optum Clinformatics® Data Mart database to 
identify demographic and clinical predictors of pharmacist-administered pediatric 
influenza vaccination compared with influenza vaccination in pediatricians’ offices.  
Procedures codes for influenza vaccinations among children were captured for the 
2016-2017 influenza season.  Logistic regression was used to identify significant 
predictors. 
Results: We included 336,841 children receiving influenza vaccines by a pharmacist 
(5.2%) or in pediatricians’ offices (94.8%).  The following significant predictors were 
identified: older age groups (13-17 years odds ratio [OR] 91.51, 5-12 years OR 35.41), 
states allowing pharmacist-administered influenza vaccination at younger ages (no age 
restrictions OR, 26.68, minimum age 2-4 years old OR, 33.76), influenza vaccination 
outside of pediatricians’ offices in the previous year (pharmacist-administered OR, 
22.18, convenience care OR 4.15, emergency care OR 1.69), geographic region (South 
OR, 2.02, Midwest OR 1.60, and West OR 1.38),  and routine health exam or follow-
up in the prior 6-months (OR, 1.59). 
Conclusions: The strongest drivers of pharmacist-administered pediatric influenza 
vaccination were older age, more lenient minimum age restrictions, and previous 




and forthcoming pediatric COVID-19 vaccines for children, pharmacists may play a 












































Historically, pediatric vaccination rates have been below the Healthy People 
2020 goal of 70% [1] and increasing access to influenza vaccines is a leading strategy 
to increase vaccination rates [2].  Pediatric vaccination often occurs in pediatrician’s 
offices, with approximately 66.8% of all pediatric vaccinations taking place in a 
doctor’s office during the 2017-2018 influenza season [3].  Beginning in the 1990s, 
various states have passed laws allowing pharmacists to administer vaccines and by 
2009, pharmacists were granted influenza vaccination authority in all states [4-6].  In 
the United States, individual states govern regulatory mandates for pharmacist-
administered vaccinations.  A common regulation is a minimum age restriction for 
pharmacist administration of influenza vaccination in children, which varies by state 
[7-9].  Positive experiences with pharmacies are common [10], and 93% of the 
population live within five miles of a pharmacy [11].  In addition, pharmacies are 
found to be more accessible with more widespread locations, have more convenient 
hours, and require less time than a pediatrician’s office visit [12, 13]. 
During the 2016-2017 influenza season, pediatric vaccination coverage 
reported by the Centers for Disease Control and Prevention (CDC) using data from the 
National Immunization Survey (NIS-Flu) was 59% [14], much lower than the Healthy 
People 2020 target of 70% [1].  Additionally, older children have lower influenza 
vaccination coverage, which has been consistently observed since 2010 [3, 15].  In the 
2016-2017 influenza season, the NIS-Flu coverage estimate for the 13-17 year old age 
group was 48.8% [14].  Children between the ages 5-17 have previously been shown 




transmission to others and vaccinating this group can reduce the impact of influenza 
within the community [16].  Based on these findings and critical need, increased 
utilization of pharmacist-administered influenza vaccination can lead to increases in 
overall vaccination rates and subsequently reduce the transmission of the influenza 
virus.  
Differences among children vaccinated by a pharmacist compared with 
children vaccinated in a pediatrician’s office are not known.  Understanding drivers 
and barriers to pharmacist-administered vaccination allows identification of target 
populations for educational interventions about pediatric influenza vaccination, 
including pharmacist vaccination of children.  Therefore, the purpose of our study was 
to determine demographic and clinical characteristics predictive of pharmacist-
administered influenza vaccination among children when compared with influenza 















The Optum Clinformatics® Data Mart Database, a claims data warehouse of 
commercially insured persons, was used to conduct this study.  The study population 
included pediatric patients, less than (<) 18 years old, who obtained an influenza 
vaccine between July 1, 2016 to June 30, 2017 as identified from Current Procedural 
Terminology (CPT) codes in Supplemental Table 1.  Patients were continuously 
enrolled for the entire influenza season and the preceding year (July 1, 2015 to June 
30, 2016).  Duplicate vaccinations within the study period were removed as it is 
recommended to be vaccinated once per season, except for initial vaccination [17].  
For the purposes of this study, the initial vaccination was considered.  The study 
population was limited to children residing in any of the 50 states or the District of 
Columbia.  Children vaccinated by pharmacists or in pediatricians’ office, including 
primary care and family medicine offices, were selected for inclusion. The study 
population identification flowchart can be found in Figure 1.   
We developed a list of potential predictors a priori, which included 
demographic characteristics (age, sex, geographic region defined by the U.S. Census 
Bureau [18]) and clinical characteristics based on International Classification of 
Diseases (ICD-10) codes in the 6 months preceding administration of the influenza 
vaccine. Clinical characteristics included the most common pediatric health conditions 
and healthcare utilization (Supplemental Table 2) and other less common 
comorbidities which increase the risk of severe influenza illness (Supplemental Table 
3). We also assessed prior influenza season vaccination status and location and age 





We compared the distribution of demographic and clinical characteristics 
among children vaccinated by pharmacists and children vaccinated in pediatricians’ 
offices. Age was assessed as a categorical variable; 6 months to 4 years old, 5 to 12 
years old, and 13 to 17 years old [14].  Using statistical software for all analyses (SAS, 
version 9.4, SAS Institute Inc., Cary, NC), the non-parametric Wilcoxon Rank Sum 
Scores was used to evaluate differences in median age.  Fisher’s exact tests and chi-
square tests were used to evaluate differences in categorical variables.  Statistical 
significance was assessed using a 2-sided test, with significance being ≤0.05.   
Logistic regression was utilized to identify predictors of pharmacist-
administered pediatric influenza vaccination.  Variables with a likelihood ratio p-value 
of less than 0.2 from the univariate analysis were selected for inclusion in the initial, 
full multivariable model [19].  Absence of multicollinearity of this model was 
confirmed.  Stepwise, backward elimination [19] was utilized to remove variables that 
were not significant (p-value >0.05 from likelihood ratio testing and Wald p-values), 
until all the variables were significant in the final model (p-value ≤ 0.05) [19].  The 











We identified 336,841 children with influenza vaccinations in the 2016-2017 
season, with 17,535 (5.2%) children vaccinated by pharmacists and 319,306 (94.8%) 
vaccinated in a pediatrician’s office.  A number of significant differences were 
observed between the groups in terms of demographic and clinical characteristics 
(Table 1).  Pharmacist-administered influenza vaccination was highest in those 13-17 
years of age (57.6% versus 21.1% in the pediatricians’ office, p<0.0001).  Among 
both groups, there were more males than females (50.3% in a pharmacy versus 51.3% 
in a pediatrician’s office, p=0.0093).  Geographic differences were observed between 
groups, the most noticeable being in the Northeast region where pharmacist-
administered influenza vaccination was the lowest (3.3% versus 14.0% in a 
pediatrician’s office, p<0.0001).  Previous year influenza vaccination was higher 
among children receiving their vaccination in a pediatrician’s office (70.4%) 
compared with pharmacist-administration (67.4%, p<0.0001).  In the pharmacist-
administered group, 52.1% of those vaccinated in the previous year had used a 
pharmacy versus 1.3% in the pediatricians’ office group (p<0.001).  Lastly, 
pharmacist-administered vaccination was more common in states with no minimum 
age restrictions (36.5%, versus 25.2% in a pediatrician’s office, p<0.0001). 
Unadjusted and adjusted odds ratios and corresponding 95% confidence 
intervals are reported in Table 2.  Our final multivariable logistic regression model 
included five statistically significant predictors of pharmacist-administered pediatric 
influenza vaccination and eight variables significantly associated with pediatricians’ 




Predictors of pharmacy-based influenza vaccination included age group, state 
restrictions, previous vaccination setting, geographic region, and recent health 
examination or follow-up.  Older age was predictive of pharmacist-administered 
vaccination with an odds ratio (OR) of 91.51 for the 13-17-year age group (95% 
confidence interval [CI] 73.49-113.94; reference group 6 months to 4 years) and OR 
of 35.41 for the 5-12 year age group (95% CI, 28.45-44.07).  States permitting 
pharmacist-administered influenza vaccination at younger ages were also predictive of 
pharmacist-administered pediatric influenza vaccination, including states with no age 
restrictions (OR, 26.68; 95% CI, 21.31-33.41; reference group did not allow 
pharmacist-administered pediatric influenza vaccination in children under 18 years 
old), and states with minimum age restrictions between 2 and 4 years old (OR, 33.76; 
95% CI, 26.466-43.07), minimum age restrictions between 5 and 12 years old and any 
age with prescription (OR, 20.93; 95% CI, 16.75-26.16),  minimum age restrictions 
between 5 and 12 years old (OR, 15.54; 95% CI, 12.43-19.43),  minimum age 
restrictions between 13 and 17 years old and any age with prescription (OR, 13.62; 
95% CI, 10.67-17.39), and minimum age restrictions between 13 and 17 years old 
(OR, 8.95; 95% CI, 6.93-11.55).   
Previous year vaccination setting was another predictor of pharmacist-
administered vaccination, including previous pharmacist-administered influenza 
vaccination (OR, 22.18; 95% CI, 21.02-23.41; reference group was unvaccinated in 
the previous year), and previous year vaccination in a convenience care (OR, 4.15; 
95% CI, 3.76-7.58), emergency care setting (OR, 1.69; 95% CI, 1.33-2.14), or other 




1.82-2.25; reference Northeast), Midwest (OR, 1.60; 95% CI, 1.45-1.77), and West 
(OR, 1.38; 95% CI, 1.24-1.55) were predictive of pharmacist-administered pediatric 
influenza vaccination, as was having a routine health examination or follow-up 
appointment in the 6-month baseline period (OR, 1.59; 95% CI, 1.53-1.65). 
Alternatively, the following were significant predictors of pediatricians’ office 
pediatric influenza vaccination: previous diagnosis of acute upper respiratory infection 
(OR, 0.91; 95% CI, 0.83-0.99); attention-deficit/hyperactivity disorder (ADHD) (OR, 
0.90; 95% CI, 0.83-0.98); Streptococcal sore throat (OR, 0.87; 95% CI, 0.79-0.96); 
cough (OR, 0.85; 95% CI, 0.77-0.94); fever (OR, 0.85; 95% CI, 0.76-0.95); obesity 
(OR, 0.84; 95% CI, 0.73-0.98); otitis media (OR, 0.79; 95% CI, 0.70-0.89);  and 

















To our knowledge, this study is the first to identify predictors of pharmacist-
administered pediatric influenza vaccination among a commercially insured pediatric 
population.  Pharmacist-administered influenza vaccination was associated with older 
age, less restrictive minimum age requirements, previous vaccination outside of the 
pediatrician’s office, region, and previous routine health examination or follow-up 
visit.   
From these results, age and minimum age restrictions were the strongest 
drivers of pharmacist-administered influenza vaccination.  Children between the ages 
of 13 and 17 were 91 times as likely to receive an influenza vaccine administered by a 
pharmacist than younger children aged 6 months to 4 years.  Previous research has 
identified parent willingness as a facilitator of pharmacist-administered pediatric 
vaccination, specifically in older children.  In a previous study conducted via online 
surveys among parents of 11-17 years old in 2014 and 2015, 62% of parents were 
willing to have a pharmacist administer the influenza vaccine to their child, which was 
higher than any other vaccine evaluated (combination tetanus, diphtheria, pertussis 
[Tdap] booster, 41%; meningococcal vaccine, 33%; human papillomavirus [HPV], 
29%) [20].  Other studies have evaluated adolescent HPV vaccine administration by 
pharmacists [12, 20-22], which found pharmacies to be more accessible, have more 
convenient hours, and require less time than a pediatrician’s office [12].  Parent 
willingness to vaccinate in a pharmacy was also found to be higher when they 
believed that pharmacists were skilled at vaccine administration, when parents thought 




vaccination would expand healthcare opportunities for children [20].  More lenient 
state-level minimum age requirements significantly increased the likelihood of 
influenza vaccination by a pharmacist.  As the minimum age at which state laws 
allowed children to be vaccinated by a pharmacist decreased, the odds of pharmacist-
administered pediatric influenza vaccination increased in a dose-response fashion 
(Figure 2) as compared with the reference group of states which do not allow 
pharmacist-administered pediatric influenza vaccination.  For example, children in 
states with no age restrictions were 27 times as likely to receive the influenza vaccine 
from a pharmacist, whereas patients in states with minimum age restrictions between 
13 and 17 years were only 9 times more likely to be vaccinated by a pharmacist.  More 
strict regulations, particularly state-governed minimum age restrictions, act as a barrier 
to pharmacist-administered pediatric influenza vaccination by limiting access to 
mainly pediatricians’ offices, rather than expanding access through community 
pharmacies.  A main goal of pharmacist-administered influenza vaccination is to 
expand access to vaccines, however, such restrictions are hindering these efforts.  
Some concerns regarding pharmacist-administered pediatric vaccination that may 
result in such limitations is that the visit with the pharmacist for a vaccine may replace 
a child’s wellness visit with their pediatrician, where the pediatrician provides 
essential care that a pharmacist cannot, such as by preventative screening, performing 
routine exams, counseling, answering questions, and establishing trusting relationships 
[23].  The findings from this study are somewhat inconsistent with the idea above, as 
children who are vaccinated in a pharmacy were 59% more likely to have a routine 




pediatrician.  For a more complete understanding, children vaccinated within a 
pharmacy would need to be followed for a period of time after vaccination to 
determine if there are significant differences in routine pediatric visits when compared 
to children vaccinated in a pediatrician’s office. 
Some states allow pharmacist-administered pediatric influenza vaccination in 
additional age groups when a physician prescription is obtained.  This form of 
expanded access for additional age groups via physician prescrption increased the 
likelihood of pharmacist-administered pediatric influenza vaccination.  In both the 5-
12-year old age group and the 13-17-year old age group, allowing pharmacists to 
vaccinate children against influenza via physician prescription increased the likelihood 
of pharmacist-administered vaccination by 500%.   
Previous vaccination in settings other than the pediatricians’ office, 
particularly pharmacist-administered pediatric influenza vaccination, was associated 
with subsequent pharmacist-administered pediatric influenza vaccination.  Children 
were 22 times as likely to receive the influenza vaccine from a pharmacist if they had 
done so in the year prior.  The increased likelihood of repeat utilization of pharmacists 
as vaccinators was also observed in a study conducted among Canadian adults during 
the 2013-2014 and 2015-2016 influenza seasons [24].  Vaccination in a pharmacy 
provides greater access to vaccination through increased convenience and efficiency 
[12], and commonly, patients find their experiences with a pharmacy positive [10].  
These positive experiences within healthcare have been shown to be facilitators of 
continued healthcare utilization.  Previous studies have found that parents were more 




previous positive experience with their pharmacy and knew their pharmacist(s) 
moderately well [21].   
Though individual states govern regulatory mandates for pharmacist-
administered vaccinations, pharmacists were granted expanded vaccination authority 
to administer any FDA authorized vaccine to children aged 3 to 18 under the “Third 
Amendment to Declaration Under the Public Readiness and Emergency Preparedness 
Act for Medical Countermeasures Against COVID–19” (PREP Act) released in 
August 2020 [25] for the duration of the Coronavirus Disease 2019 (COVID-19) 
pandemic.  The United States Health and Human Services Department (HHS) 
recognized pharmacists were well-positioned to expand access to all childhood 
vaccinations to combat the alarming decline in routine pediatric vaccines observed 
during the onset of the pandemic [25, 26].   
This amendment is recent and the effectiveness of these changes, specifically 
utilization of pharmacist-administered pediatric vaccination, is not yet known.  Other 
unknowns include parental awareness of this expanded access to vaccination in 
community pharmacies in states which had older minimum age restrictions, the 
duration of this expanded access, and the influence of the PREP Act on future 
vaccination practices.  According to our study, previous influenza vaccination by a 
pharmacist was a strong predictor of subsequent influenza vaccination.  This has 
important implications if pharmacists become the primary administrators of COVID-
19 vaccines for children and/or if pharmacists become utilized more frequently for 
typical childhood vaccines.  A first experience utilizing pharmacist-administered 




continued utilization in that setting.  Because of this expansion in access to 
vaccination due to the PREP Act, it will be important to evaluate, in future research, 
the uptake of pharmacist-administered vaccination for influenza and all pediatric 
vaccinations, including COVID-19 vaccines, when compared to pediatricians’ offices, 
and determine whether the utilization changes observed are temporary changes or 
sustained changes that increase pharmacy vaccination among children. 
Children in regions outside of the Northeast were also more likely to be 
vaccinated against influenza by a pharmacist.  Historically, the Northeast region of the 
United States, categorized by the U.S. Census Bureau [18], has the highest vaccination 
rates in the country [27, 28].  However, from our analysis, children living in the South 
were 2 times more likely to be vaccinated by a pharmacist when compared to the 
Northeast.  Aside from West Virginia and Florida, all other states in the South allow 
pharmacist-administered pediatric influenza vaccination of various age limitations, 
compared to the Northeast where pharmacists can administer the influenza vaccine 
only to adults 18 years of age and older in Vermont, Massachusetts, Connecticut, and 
New York [7].  It is possible that in this region of the country, pharmacies are much 
more accessible than pediatrician’s offices in terms of number of pharmacies and 
proximity to patients.  Patients may utilize pharmacies more for reasons outside of 
vaccination or there may be more awareness of pharmacist-administered pediatric 
influenza vaccination among children and their families in this region as well.  These 
regional differences in influenza vaccination rates may be a sign of regional 
differences that can be expected of COVID-19 vaccination rates for adults and 




COVID-19 vaccines, and as part of the Federal Retail Pharmacy Program for COVID-
19 Vaccination, have distributed nearly 94 million doses of COVID-19 vaccine at the 
time this manuscript was authored [29]. 
Factors associated with vaccination in the traditional pediatricians’ office 
setting were pre-existing conditions, including obesity, severe developmental delay, 
ADHD, and infectious conditions, which require more frequent pediatricians’ office 
visits, and therefore vaccinating within that setting may be more convenient for 
parents and caregivers.  Similarly, pre-existing conditions of diabetes, hypertension, 
chronic obstructive pulmonary disorder, asthma, congestive heart failure, and acute 
myocardial infarction among adults were found to be predictors of vaccination in a 
physician’s office [24].  Obesity and developmental delay are associated with 
increased risk of severe influenza infection and complications [30, 31], and therefore 
may prompt reminders for influenza vaccination scheduling at those visits.  Healthy 
children without these conditions may only be seen for their annual check-up.  If that 
visit does not coincide with the height of the influenza vaccination season, families 
may face barriers in scheduling a separate visit solely for the influenza vaccine, such 
as time away from work for parents/caregivers and time away from school for 
children.  At annual visits, physicians’ offices could provide a list of available 
providers of pediatric influenza vaccination, including area pharmacies, to encourage 
vaccination in whichever setting is most comfortable and convenient for each family.  
Aside from age, age restrictions, and parent willingness, low pharmacist-
administered influenza vaccination may be attributed to lack of awareness of 




immunization delivery programs and workflows across different pharmacies can limit 
the receptivity of pharmacist-administered influenza vaccination by patients, 
caregivers, and pediatricians [33].  In addition, patients, caregivers, and physicians 
may have concerns that vaccination outside of the pediatricians’ office or outside of 
the pediatricians’ office health system may result in inaccurate or incomplete 
vaccination records and documentation due to limited access to electronic medical 
records and/or immunization information systems (IIS) by pharmacists [33].   
Parent willingness to vaccinate their children against influenza from any 
provider has also been associated with their child having had a previous influenza 
vaccine, other family members regularly vaccinated against influenza, and perceived 
safety and lack of side effects, determined from a survey study in 2011 [34].  Other 
factors that can influence influenza vaccination or act as barriers to vaccination are 
parental perceptions of susceptibility to influenza virus and vaccine risk [35], 
unhealthy lifestyles, lack in access to care, socioeconomic status, and education [36].  
Commonly reported reasons for parents and/or caregivers to not vaccinate their 
children include lack of awareness of influenza vaccine recommendations and fear of 
side effects [37].  Hesitancy toward vaccinations is also an increasing trend [13, 33, 
38].  However, pharmacists can play an essential role in educating patients and 
caregivers about the benefits of vaccination and correcting any misconceptions they 
may have [13, 33], which has been shown to increase vaccination rates in adults [13].   
Limitations 
The study population was limited to pediatric patients from a single 




patients with Medicaid, which is estimated to include approximately 30 million 
children [39].  The proportion of children who were enrolled in the database varied by 
state, which includes number of enrollees and differences in demographic and clinical 
characteristics, which may attribute to differences in vaccination by region.  Our study 
is limited to the accuracy and consistency of coding in the claims database for 
influenza vaccination claims, categorization of provider setting, and for claims of the 
clinical comorbidities of interest.  Typically, nurses or nurse practitioners administer 
vaccines in the pediatric primary care setting, however there were several provider 
category codes for nurse/nurse practitioner that do not specify an additional 
description of primary care or pediatricians’ office and were therefore not included in 
this study.  This has the potential to reduce the number of influenza immunizations 
included in the pediatricians’ office setting. Only the first influenza vaccine in each 
season was included and it is possible a different provider setting was used in cases 
where children received a second vaccine. In our study population, several 
comorbidities evaluated had very low frequencies and may be significant if the 
database was larger.  Lastly, we evaluated patient demographics and clinical 
characteristics available from the claims database, and certain potential predictors, 
such as race, are not available from the database and therefore could not be captured.  
A similar study carried out using a different database that includes race could be used 








We found the utilization of pharmacist-administered pediatric influenza 
vaccination in our study to be low compared to vaccination within a pediatrician’s 
office and compared to pharmacist-administered adult influenza vaccination.  The 
strongest drivers of pharmacist-administered influenza vaccination were older age, 
less restrictive minimum age requirements, and previous vaccination in a pharmacy.  
Current minimum age restrictions have been shown to act as barrier to pharmacist-
administered pediatric influenza vaccination, however, the current PREP Act overrides 
any state governed minimum age restrictions, and pharmacists have been granted 
authority to administer any FDA authorized vaccine to children 3 years of age and 
older in all states [25].  Pharmacists will play an important role in increasing 
vaccination rates among children for influenza and all pediatric vaccines, including 
COVID-19 vaccines when they are authorized for children.  Additionally, previous 
vaccination in a pharmacy was a driver of pharmacist-administered pediatric influenza 
vaccination.  Considering these two major findings, more children, particularly 
younger children, may be utilizing pharmacists more for any vaccination for the 
duration of the PREP Act, which has been shown to drive continued utilization in that 
setting.  It will be important to study whether the utilization changes are temporary 
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3.8 TABLES AND FIGURES 











6 months to 4 years 82 (0.5%) 91,421 (28.6%) 
5 to 12 years 7,346 (41.9%) 160,451 (50.3%) 
13 to 17 years 10,107 (57.6%) 67,434 (21.1%) 
Sex     
0.0093  Female 8,723 (49.8%) 155,623 (48.7%) 
Male 8,812 (50.3%) 163,683 (51.3%) 
Region     
<0.0001 
Midwest 4,769 (27.2%) 91,326 (28.6%) 
Northeast 570 (3.25%) 44,808 (14.0%) 
South 7,508 (42.8%) 118,873 (37.2%) 
West 4,688 (26.7%) 64,299 (20.1%) 
Previous year vaccination     
<0.0001 No 5,715 (32.6%) 94,456 (29.6%) 
Yes 11,820 (67.4%) 224,850 (70.4%) 
Previous year vaccination setting     
<0.0001  Pediatricians’ office 4,575 (38.7%) 211,794 (94.2%) 




Convenience care 608 (5.1%) 2,473 (1.1%) 
Emergency care 81 (0.7%) 926 (0.4%) 
Other settings 397 (3.4%) 6,815 (3.0%) 
State Pharmacist Authorization Model, Age Restrictions 
<0.0001  
No age restriction 6,406 (36.5%) 80,384 (25.2%) 
Minimum 2-4 years old 813 (4.6%) 8,158 (2.6%) 
Minimum 5-12 years old and any  
     age with physician prescription 
5,600 (31.9%) 76,957 (24.1%) 
Minimum 5-12 years old 3,863 (22.0%) 93,508 (29.3%) 
Minimum 13-17 years and any  
     age with physician prescription 
479 (2.7%) 9,287 (2.9%) 
Minimum 13-17 years old1 292 (1.7%) 8,943 (2.8%) 
Minimum 18 years old 82 (0.5%) 420,699 (13.2%) 
Healthcare Utilization and Common Pediatric 
Conditions  
    
Abdominal pain 343 (2.0%) 5,163 (1.6%) 0.0006 
Acute pharyngitis 1,587 (9.1%) 35,420 (11.1%) <0.0001 
Acute upper respiratory infection 822 (4.7%) 29,960 (9.4%) <0.0001 
Allergic rhinitis 1,230 (7.0%) 18,221 (5.7%) <0.0001 
Attention-deficit/hyperactivity 
disorder 
840 (4.8%) 11,105 (3.5%) <0.0001 
Bronchitis 168 (1.0%) 3,822 (1.2%) 0.0044 




Constipation, unspecified 187 (1.1%) 5,016 (1.6%) <0.0001 
Cough 589 (3.4%) 19,336 (6.1%) <0.0001 
Dermatitis 96 (0.6%) 1,491 (0.5%) 0.1295 
Esophageal reflux 137 (0.8%) 2,428 (0.8%) 0.7566 
Fever 442 (2.5%) 21,639 (6.8%) <0.0001 
Gastroenteritis/colitis 101 (0.6%) 2,589 (0.8%) 0.0007 
Influenza  68 (0.4%) 1,768 (0.6%) 0.0037 
Otitis media 391 (2.2%) 20,662 (6.5%) <0.0001 
Pneumonia 107 (0.6%) 3,916 (1.2%) <0.0001 
Prophylactic vaccination 3,196 (18.2%) 51,915 (16.3%) <0.0001 
Routine child health exam/follow-
up 
6,766 (38.6%) 108,547 (34.0%) <0.0001 
Sinusitis 176 (1.0%) 2,928 (0.9%) 0.2420 
Streptococcal sore throat 541 (3.1%) 15,234 (4.8%) <0.0001 
Urinary tract infection, cystitis 154 (0.9%) 2,959 (0.9%) 0.5139 
Viral diseases 220 (1.3%) 9,703 (3.0%) <0.0001 
Other Less Common Pediatric Conditions     
Blood disorders    
Sickle cell anemia 5 (0.0%) 68 (0.0%) 0.5272 
Hemoglobinopathy 4 (0.0%) 27 (0.0%) 0.0755* 
Thalassemia major 0 (0.0%) 21 (0.0%) 0.6247* 
Cardiac disease       




Congenital heart disease 8 (0.0%) 207 (0.1%) 0.3269 
Coronary artery disease 0 (0.0%) 3 (0.0%) 1.0000* 
Cognitive disorders       
Intellectual disability 15 (0.1%) 233 (0.1%) 0.5501 
Severe developmental delay 93 (0.5%) 6,009 (1.9%) <0.0001 
Spinal cord injury 3 (0.0%) 99 (0.0%) 0.4980* 
Hepatic conditions       
Chronic liver disease with cirrhosis 0 (0.0%) 4 (0.0%) 1.0000* 
Immunocompromised conditions       
HIV/AIDS 1 (0.0%) 10 (0.0%) 0.4446* 
Cancer 31 (0.2%) 350 (0.1%) 0.0100 
Chemotherapy 1 (0.0%) 42 (0.0%) 0.7266* 
Chronic corticosteroid therapy 4 (0.0%) 66 (0.0%) 0.7851* 
Metabolic/Endocrine conditions        
Diabetes (Type 1)  97 (0.6%) 827 (0.3%) <0.0001 
Diabetes (Type 2)  16 (0.1%) 179 (0.1%) 0.0593 
Neurologic conditions       
Cerebral palsy 25 (0.1%) 525 (0.2%) 0.4854 
Muscular dystrophy 1 (0.0%) 60 (0.0%) 0.3778* 
Neuromuscular disease  3 (0.0%) 88 (0.0%) 0.6334* 
Epilepsy 0 (0.0%) 11 (0.0%) 1.0000* 
Obesity 248 (1.4%) 3,262 (1.0%) <0.0001 




Respiratory disease             
Asthma 1,006 (5.7%) 15,635 (4.9%) <0.0001 
Chronic lung disease 0 (0.0%) 17 (0.0%) 1.0000* 
Chronic obstructive pulmonary 
disease  
71 (0.4%) 1,477 (0.5%) 0.2717 
Cystic fibrosis 9 (0.1%) 76 (0.0%) 0.0255 
Pediatric emphysema 0 (0.0%) 13 (0.0%) 1.0000* 
*Fishers exact test was used due to low incidence of condition  
Note: Healthcare utilization, common pediatric conditions, and pediatric comorbidities were 
assessed in 6-month period prior to vaccination.
 
Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, 
New York, New Jersey, Pennsylvania 
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North 
Dakota, South Dakota, Nebraska, Kansas 
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, 
Maryland, Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, 
Arkansas, Louisiana, Oklahoma, Texas 
West: Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, 
Alaska, Hawaii, New Mexico, Arizona 
















Age Group   
6 months to 4 years Ref Ref 
5 to 12 years 51.04 (41.05-63.46) 35.41 (28.45-44.07) 
13 to 17 years 167.10 (134.43-207.70) 91.51 (73.49-113.94) 
Sex   
Male Ref - 
Female 1.04 (1.01-1.07) - 
Region   
Northeast Ref Ref 
Midwest 4.11 (3.76-4.48) 1.60 (1.45-1.77) 
South 4.97 (4.56-5.41) 2.02 (1.82-2.25) 
West 5.73 (5.25-6.26) 1.38 (1.24-1.55) 
Previous Year Vaccination   
No Ref - 
Yes 0.87 (0.84-0.90) - 
Previous Year Vaccination Setting  
Not previously vaccinated Ref Ref 
Pediatricians’ Office 0.36 (0.34-0.37) 0.51 (0.49-0.53) 




Convenience Care 4.06 (3.70-4.46) 4.15 (3.76-4.58) 
Emergency Care 1.45 (1.15-1.82) 1.69 (1.33-2.14) 
Other Settings 0.96 (0.87-1.07) 1.13 (1.01-1.25) 
State Pharmacist Authorization Model, Age Restrictions 
Does not allow,  
     Minimum 18 years old 
Ref Ref 
No age restriction 40.88 (32.87-50.85) 26.68 (21.31-33.41) 
Minimum 2-4 years old 51.12 (40.69-64.24) 33.76 (26.46-43.07) 
Minimum 5-12 years old  
     and any age w/ Rx 
37.33 (30.01-46.44) 20.93 (16.75-26.16) 
Minimum 5-12 years old 21.19 (17.02-26.38) 15.54 (12.43-19.43) 
Minimum 13-17 years old  
     and any age w/ Rx 
26.46 (20.91-33.48) 13.62 (10.67-17.39) 
Minimum 13-17 years old1 16.75 (13.10-21.42) 8.95 (6.93-11.55) 
Healthcare Utilization and Common Pediatric Conditions 
Abdominal pain 1.21 (1.09-1.36) - 
Acute pharyngitis 0.80 (0.76-0.84) - 
Acute upper respiratory infection 0.48 (0.44-0.51) 0.91 (0.83-0.99) 
Allergic Rhinitis 1.25 (1.17-1.32) - 
Attention-deficit/hyperactivity  
     disorder 
1.40 (1.30-1.50) 0.90 (0.83-0.98) 
Bronchitis 0.80 (0.68-0.93) - 




Constipation 0.68 (0.58-0.78) - 
Cough 0.54 (0.50-0.59) 0.85 (0.77-0.94) 
Dermatitis 1.17 (0.95-1.44) - 
Fever 0.36 (0.32-0.39) 0.85 (0.76-0.95) 
Gastroenteritis/colitis 0.71 (0.58-0.87) - 
Influenza  0.70 (0.55-0.89) - 
Otitis media 0.33 (0.30-0.37) 0.79 (0.70-0.89) 
Pneumonia 0.50 (0.41-0.60) - 
Prophylactic vaccination 1.15 (1.10-1.19) - 
Routine child health 
examination/follow-up 
1.22 (1.18-1.26) 1.59 (1.53-1.65) 
Streptococcal sore throat 0.64 (0.58-0.69) 0.87 (0.79-0.96) 
Viral diseases 0.41 (0.36-0.46) - 
Other Less Common Pediatric Conditions   
Blood disorders   
Hemoglobinopathy 2.71 (0.95-7.73) - 
Cognitive disorders   
Severe developmental delay 0.28 (0.23-0.34) 0.66 (0.53-0.83) 
Immunocompromised conditions  
Cancer 1.61 (1.12-2.33) - 
Metabolic/Endocrine conditions   
Diabetes (Type 1)  2.14 (1.74-2.65) - 




Neurologic conditions   
Muscular Dystrophy 0.31 (0.04-2.19) - 
Obesity 1.39 (1.22-1.59) 0.84 (0.73-0.98) 
Renal Disease 0.27 (0.04-1.96) - 
Respiratory disease         
Asthma 1.18 (1.11-1.26) - 
Cystic fibrosis 2.16 (1.08-4.31) - 
 
Rx = Prescription  
Note: Healthcare utilization, common pediatric conditions, and pediatric comorbidities were 
assessed in 6-month period prior to vaccination. 
 
Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, 
New York, New Jersey, Pennsylvania 
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North 
Dakota, South Dakota, Nebraska, Kansas 
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, 
Maryland, Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, 
Arkansas, Louisiana, Oklahoma, Texas 
West: Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, 
Alaska, Hawaii, New Mexico, Arizona 






Figure 1. Flowchart of inclusion and exclusion criteria  
Pediatric influenza vaccinations 
from July 1, 2016 – June 30, 2017 



















Continuous enrollment from  
July 1, 2015 to June 30, 2017  
(n = 382,282) 
Initial pediatric 
influenza vaccinations 
(n = 376,770) 
Duplicate pediatric influenza 
vaccinations excluded 
(n = 5,512) 
Vaccination setting: 
pediatricians’ office or 
pharmacist-administered 
(n = 336,841) 
Pediatricians’ office  
(n = 319,306) 
Pharmacist-administered  
(n = 17,535) 
Non-missing 
sex and state  
(n = 376,074) 
Unknown sex (n= 2) and 
state (n=690) and Puerto 
Rico (n=4) excluded 
Convenience care (n=9,542), 
emergency care (n=3,286), 





Figure 2. Forest plot of significant predictors of pharmacist-administered influenza 
vaccination in children 














Previous Vaccine Other setting
Previous Vaccine Emergency care
Previous Vaccine Convenience care
Previous Vaccine Pharmacy
Min 13-17 years old*
Min 13-17 years old (Any age with Rx)*
Min 5-12 years old*
Min 5-12 years old (Any age with Rx)*
Min 2-4 years old*
No Age Restrictions*
Patient age 5-12 years old
Patient age 13-17 years old
Odds ratio
* 
Minimum age requirement for pharmacist-administered influenza vaccination. 
Rx=Prescription  
Note: Healthcare utilization, common pediatric conditions, and pediatric comorbidities were assessed in 
6-month period prior to vaccination. 
 
Northeast (Ref): Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New 
York, New Jersey, Pennsylvania 
Midwest: Ohio, Indiana, Michigan, Illinois, Wisconsin, Missouri, Iowa, Minnesota, North Dakota, 
South Dakota, Nebraska, Kansas 
South: West Virginia, District of Columbia (DC), Virginia, North Carolina, Kentucky, Maryland, 
Delaware, Tennessee, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas, Louisiana, 
Oklahoma, Texas 
West: Montana, Wyoming, Colorado, Utah, Idaho, Nevada, Washington, Oregon, California, Alaska, 




Supplemental Table 1. International Classification of Diseases Version 10 (ICD-10) 
codes for healthcare utilization and common pediatric diagnoses  
Condition (33) ICD 10 
Routine child health examination or 
Follow-up examination  
Z00.121, Z00.129 
Z09 
Acute upper respiratory infection J06.9 
Otitis media 
H65.01 - H65.06, H65.21 - H65.23, 
H65.111 - H65.116, H65.411 - 
H65.413, H66.001 - H66.003,  
H66.011 - H66.013, H66.004 - 
H66.006, H66.014 - H66.016, H66.11 
- H66.13, H66.21 - H66.23 
Acute pharyngitis J02.9 
Allergic rhinitis J30.1, J30.89, J30.9 
Sinusitis J32.0 - J32.4, J32.8, J32.9 
Dermatitis 
L23.0 - L23.2, L23.4 - L23.7, L23.81, 
L23.89, L23.9, L24.0 - L24.3, L24.5 - 
L24.7, L24.81, L24.89 
Attention-deficit/hyperactivity disorder F90.0, F90.1, F90.2, F90.8 
Cough R05 
Streptococcal sore throat J02.0 
Bronchitis J20.5, J20.6, J20.9 




B30.1,  B30.9 
Esophageal reflux K21.0, K21.9, P78.83 
Influenza  
J09X1, J09X2, J09X3, J09X9, J10.1, 
J10.2, J10.00, J10.01, J10.08, J10.81, 
J10.82, J10.83, J10.89, J11.1, J11.2, 
J11.00, J11.08, J11.81, J11.82, J11.83, 
J11.89 
Gastroenteritis/colitis K52.9 
Fever R50.83, R50.9 
Constipation, unspecified K59.00 
Prophylactic vaccination Z23 
Abdominal pain 
R10.13, R10.83, R10.84, R10.0, 
R10.31 - R10.33,  
R10.11, R10.12 
Viral diseases B33.8, B34.9 
Pneumonia J12.9, J18.0, J18.1, J18.8, J18.9 
Urinary tract infection, cystitis (34) 
N30.00, N30.01, N30.10, N30.11, 
N30.20, N30.21, N30.30, N30.31, 
N30.40, N30.41, N30.80, N30.81, 




Supplemental Table 2. International Classification of Diseases Version 10 (ICD-10) 
codes for underlying health conditions which increase the risk of severe influenza 
infection 
Condition ICD 10 
Blood disorders (27, 35, 36)       
     Hemoglobinopathy D58.2 
     Sickle cell anemia 
D57.00 – D57.02, D57.1, 
D57.20,  D57.211, D57.212, 
D57.219, D577.3, D57.40, 
D57.411, D57.412, D57.419, 
D57.80, D57.811, D57.812, 
D57.819 
     Thalassemia major D56.5, D56.8, D56.9 
Cardiac disease (27, 35, 36)  
     Atherosclerotic heart disease 
I25.10, I25.110, I25.111, 
I25.118, I25.119 
     Congenital heart disease 
Q20.8, Q20.9, Q21.8, Q21.9 , 
Q24.6, Q24.8, Q24.9 
     Coronary artery disease 
I25.750, I25.751, I25.758, 
I25.759, I25.811, I25.82 
Cognitive disorders (28, 36)  
     Intellectual disability F70, F71, F72, F73, F78, F79 




F80.81, F80.82, F80.89, F80.9, 
F82, F88, F89 
     Spinal cord injury 
G32.0, G95.11, G95.89, G95.9, 
Q06.8, Q06.9 
Hepatic conditions (36)  
     Chronic liver disease with cirrhosis 
K74.3, K74.4, K74.5, K74.60, 
K74.69 
Immunocompromised conditions (27, 35, 36)  
     HIV/AIDS B20 
     Cancer C00.0-C96.9 
     Chemotherapy Z51.0, Z51.11, Z51.12, 
     Chronic corticosteroid therapy Z79.52, Z92.241 
Metabolic/Endocrine conditions (27, 36, 37)  
     Diabetes (Type 1)  
     Diabetes (Type 2)  
E10.65, E10.9 
E11.65, E11.9 
Neurologic conditions (35, 36)  
     Cerebral palsy 
G80.3, G80.0, G80.1, G80.2, 
G80.4, G80.8, G80.9 
     Muscular dystrophy G71.0, G71.11 
     Neuromuscular disease 
 
M41.40, M41.41, M41.42, 
M41.43, M41.44, M41.45, 
M41.46, M4147 





Obesity (27, 36) 
E66.01, E66.09, E66.1, E66.2, 
E66.8, E66.9, Z68.54 
Respiratory disease (27, 35, 36)             
     Asthma 
 
J45.20, J45.21, J45.22, J45.30, 
J45.31, J45.32, J45.40, J45.41, 
J45.42, J45.50, J45.51, J45.52, 
J45.990, J45.901, J45.902, 
J45.909, J45.991, J45.998 
     Chronic lung disease 
J68.4, J70.1, J70.3, J84.848, 
J84.89, J84.9 
     Chronic obstructive pulmonary disease  J40, J41.0, J41.1, J41.8, J42 
     Cystic fibrosis 
E84.0, E84.11, E84.19, E84.8, 
E84.9 
     Pediatric emphysema J43.0, J43.1, J43.2, J43.8, J43.9,  
     Renal disease (27, 36) 
N01.0, N01.1, N01.2, N01.3, 
N01.4, N01.5, N01.6, N01.7, 
N01.8, N01.9, N03.0, N03.1, 
N03.2, N03.3, N03.4, N03.5, 
N03.6, N03.7, N03.8, N03.9, 
N04.0, N04.1, N04.2, N04.3, 
N04.4, N04.5, N04.6, N04.7, 




N07.2, N07.3, N07.4, N07.5, 











Increased proportions of state-level pediatric pharmacist-administered influenza 



















Background: Pharmacists are known to increase access to vaccines through increased 
convenience, however, utilization of pharmacists for pediatric influenza vaccination 
remains low.  The impact of pharmacist-administered pediatric influenza vaccination 
on pediatric influenza diagnoses is not well described.   
Objectives: To evaluate the association between the state-level proportion of 
pharmacist-administered pediatric influenza vaccinations on the state-level proportion 
of pediatric influenza diagnoses using a retrospective ecologic study design.   
Methods: We included vaccinated children from the de-identified Optum 
Clinformatics® Data Mart database.  The proportion vaccinated by pharmacists and 
the proportion diagnosed with influenza were aggregated at the state-level during the 
2016-2017 influenza season, along with potential confounders. We assessed the 
association between state-level pediatric pharmacist-administered influenza 
vaccination and influenza diagnoses using backward manual stepwise beta regression. 
Results: The proportion of children that received an influenza vaccine in a pharmacy 
varied widely by state.  At a state level, we found that influenza diagnoses among 
children decrease by 6.2% (p=0.0369) per every additional 1% of children vaccinated 
by a pharmacist, after controlling for potential confounding factors.   
Conclusions: Pharmacists have been granted expanded authority to vaccinate children 
due to the COVID-19 pandemic. While unclear how long this expanded access will 
last, fewer influenza diagnoses were observed in states with higher pharmacist-




decrease the significant burden of influenza in children and throughout communities.  
Additionally, pharmacists can play a key role as vaccine providers and reducing rates 

























 Pharmacists have been authorized to administer the influenza vaccine in all 50 
states since 2009 (1-3).  As of September 2020, according to the American 
Pharmacists Association (APhA) and the National Alliance of State Pharmacy 
Associations (NASPA), pharmacists in all but three states (Connecticut, Florida, and 
Vermont) are allowed to administer the influenza vaccine to children, however, 
regulatory limitations are in place, such as state-specific minimum age requirements 
(4, 5).  Recently, superseding any state specific restrictions is the “Third Amendment 
to Declaration Under the Public Readiness and Emergency Preparedness Act for 
Medical Countermeasures Against COVID–19” (PREP Act) set forth by the United 
States Health and Human Services Department (HHS), which is another expansion of 
pharmacist immunization authority put into effect in August 2020.  The PREP Act 
authorizes pharmacists in all states to administer any FDA authorized vaccine to 
children aged 3 to 18 under the for the duration of the Coronavirus Disease 2019 
(COVID-19) pandemic in efforts to combat the alarming decline in routine pediatric 
vaccines observed during the current pandemic (6).    
Vaccination in a non-medical setting, such as a pharmacy, can improve access 
to vaccination through additional convenience with expanded hours and without the 
need for an appointment (2).  Vaccination within a pharmacy has proven to increase 
influenza vaccination coverage among adults (7, 8) as well as be more cost effective 
with lower average direct costs when compared to physician offices (16%-26% less) 




if pediatric influenza vaccinations within a pharmacy setting have an effect on 
pediatric influenza diagnoses.  
Therefore, the objective of this study was to evaluate the state-level association 
between the proportion of pharmacist-administered pediatric influenza vaccination on 
cumulative incidence of pediatric influenza diagnoses in an outpatient setting using 
beta regression.  An increase in the overall state-level influenza vaccination by 
pharmacists along with a decrease in outpatient influenza diagnoses may suggest that 




















A retrospective ecologic study design was used to determine the association 
between state level proportion of pharmacist-administered pediatric influenza 
vaccination and state-level pediatric influenza outpatient diagnoses using the 
Optum Clinformatics® Data Mart Database, a claims data warehouse of commercially 
insured persons.  Our study population included pediatric patients, less than (<) 18 
years of age, who obtained an influenza vaccine between July 1, 2016 to June 30, 
2017, which is representative of one influenza season (10), using Current Procedural 
Terminology (CPT) codes in Supplementary Data Table 1, obtained via 
Optum Clinformatics®Data Mart Database, a claims data warehouse of commercially 
insured persons, containing eligibility and demographic data.  Inclusion and exclusion 
criteria for the study population was previously described (11).  The index date was 
defined as the date of vaccination, and the follow up period began on the 15th day after 
vaccination to allow 2 weeks for appropriate immune response to the vaccine (10) and 
continued until the end of the influenza season, which we considered June 30, 2017.  
Figure 1 is a graphical depiction of the study period timeline. 
In this ecologic study, each child was only counted once and then aggregated 
at the state level where each state served as an individual observation.  The exposure 
(pharmacist-administered influenza vaccination), outcome (outpatient influenza 
diagnoses, International Classification of Diseases, 10th Edition codes J09.x, J10.x, 
and J11.x), and potential confounders (demographics, comorbidities, and state-level 




children with each variable by the total number of pediatric patients vaccinated against 
influenza in each state to calculate state-level proportions.   
The independent variable, defined as the proportion of children vaccinated 
within each state by a pharmacist during the study period (the number of children in a 
particular state vaccinated against influenza by a pharmacist divided by all children 
vaccinated against influenza within that abovementioned state) was also reported as a 
proportion. The remainder of independent variables, demographic and clinical 
characteristics by state proportions of the vaccinated population, as well as overall 
state-level pediatric influenza immunization coverages, which were available from 
previous work using the same database (12) were included as confounders.  Age was 
assessed as a categorical variable, mimicking the categories used by the CDC (13). 
Statistical Analysis 
Using statistical software for all analysis, SAS (version 9.4, SAS Institute Inc., 
Cary, NC), beta regression (14, 15) using a generalized linear model was used to 
quantify the association between state-level cumulative incidence of influenza 
outpatient diagnoses and the proportion of children vaccinated against influenza 
within each state by a pharmacist, while controlling for confounders.  Beta regression 
was selected as all values being analyzed are reported as state-level proportions 
between 0 and 1 (15).  The cumulative incidence of influenza outpatient diagnoses 
was modeled against the primary and secondary independent variables, and the 
proportion of children vaccinated against influenza within each state by a pharmacist 
was modeled against the secondary independent variables, potential confounders, 




the proportion of pharmacist vaccinated, then both univariate models were run with 
one independent variable at a time.  The chi-squared of the difference of the -2 Log 
Likelihood ratios from the empty model were compared to the univariate model and 
included in the multivariate model if the chi-squared for both models was less than (<) 
0.1.  Potential confounders showed association with both the state-level proportion of 
children vaccinated by a pharmacist and the cumulative incidence of influenza 
diagnoses.  Significant confounders were either statistically significant or determined 
to be important to the conceptual model by the authors.   
A full multivariate generalized linear regression model was used to model the 
state-level cumulative incidence influenza outpatient diagnoses against proportion of 
children vaccinated against influenza by a pharmacist along with significant 
confounders from the univariate model.  Clinical characteristics that were significant 
as previously identified (11) and had significant chi-squared from the univariate with 
influenza diagnosis model were also included in the multivariate model.  Also 
included in the multivariate model was region and pharmacist authorization model as 
categorical variables in the class statement.  Multicollinearity of the initial model was 
assessed using variance inflation factor (VIF), and no variables were removed.  
Backward manual elimination, unconditional stepwise beta regression (15) was 
utilized on the multivariate generalized linear regression model from above.  Any 
remaining variables that were not significant, (p-value >0.05), were removed from the 
model, in a stepwise manner with the least significant removed first, until all the 
variables in the multivariate model are significant (p-value ≤ 0.05) or determined 




influenza vaccine to children within each state included in the final multivariate model 
along with age group, though not statistically significant, but deemed clinically 
relevant by the authors.  The final model was assessed for goodness-of-fit using 
pseudo R2 (15). 
The parameter estimate, the change in cumulative incidence influenza 
diagnoses resulting from each unit change in the independent variable, the proportion 
of children vaccinated against influenza by a pharmacist, was the final output 
calculated using the multivariate model above.  Statistical significance was assessed 
using a 2-sided test, with significance being ≤0.05, and 95% Confidence Interval (CI).  













A total of 336,841 influenza-vaccinated children were identified in the study 
population during the 2016-2017 season, with 17,535 (5.2%) vaccinated by a 
pharmacist.  From the total children vaccinated, 8,442 children were diagnosed with 
influenza in an outpatient setting.  State-level pediatric influenza vaccinations by a 
pharmacist and influenza diagnoses, along with demographic and clinical 
characteristics can be found in Table 1.  
There were no instances of pharmacist-administered pediatric influenza 
vaccination in Hawaii, South Dakota, and Wyoming within the study population and 
in Washington, the pharmacist-administered influenza vaccination rate was 28.4%.  In 
2016, when the study population was captured, Hawaii allowed pharmacists to 
vaccinate children 14 years of age and older provided they presented to the pharmacy 
with a prescription from their pediatrician, and in Wyoming pharmacists had the 
independent authority to vaccinate children 7 years of age and older (14).  
Interestingly, children of any age can receive an influenza vaccine from a pharmacist 
in both South Dakota and Washington (14).  Alaska and Vermont did not have any 
documented outpatient influenza diagnoses among the study population.  To run the 
beta regression, the above-mentioned states with 0 influenza diagnoses or 0 
pharmacist-administered influenza vaccinations were changed to 0.00001.  A 
sensitivity analysis was also performed by removing the state of Washington as a 
potential outlier due to the very high proportion of children vaccinated within a 
pharmacy.  The model was repeated without Washington and the results remained 




The unadjusted and adjusted parameter estimates for the association between 
pharmacist-administered pediatric influenza vaccination and influenza diagnoses and 
corresponding 95% confidence intervals (CIs) are reported (Table 2).  After removing 
non-significant variables, the final multivariable model included 8 independent 
variables.  Pharmacist-administered influenza vaccination, pharmacist authorization 
model age restriction (added as a class), chronic pulmonary disease (COPD), routine 
health exam or follow up, prophylactic vaccination, and fever were all statistically 
significant (p<0.05).  Although not statistically significant, age group and geographic 
region were retained in the model due to epidemiologic relevance of age (15) and 
geographic region (16, 17).   
The parameter estimate for the proportion of children vaccinated by a 
pharmacist was -6.19 (95% CI -11.98 to -0.40, p=0.0369), corresponding to a 
significant decrease of 6.2% influenza diagnoses for every additional 1% of children 
vaccinated in a pharmacy. 
A sensitivity analysis was performed by re-running the analysis using both the 
5-12-year-old age group and the 13-17-year-old age group separately.  Independently, 
both age groups did not result in observed significant decreases in influenza diagnoses 









Our state-level ecologic study provides supportive evidence that higher rates of 
pharmacist-administered pediatric influenza vaccination decreases pediatric outpatient 
influenza diagnoses by 6.2% for every 1% increase in vaccination by a pharmacist. It 
is possible that, by expanding access to vaccine access due to regulations granting 
authority to pharmacists to vaccinate children, influenza vaccination coverage may be 
increasing, as has been previously observed in adults (7, 8).  This expanded access to 
vaccination has shown to reduce influenza diagnoses. 
In previous work, older age was identified as a significant driver of pediatric 
pharmacist-administered influenza vaccination, where children 13 to 17 years old and 
5 to 12 years old were 92 times and 35 times more likely to use pharmacy based 
influenza vaccination services, respectively and utilization of pharmacists as 
vaccinators has been shown to primarily take place in children between the ages of 13-
17 years old, 57.6%; and 5-12 years old, 41.9% using the same influenza season and 
study population presented in this research (11).  This 13-17-year-old age group was 
also associated with the highest increase in influenza vaccination rates over 7 
influenza seasons from 2010-2017, increasing annually by 6%, followed by an annual 
increase in pharmacist-administered influenza vaccination of 1.9% in children 5-12 
years old (18).  Overall, pharmacist-administered pediatric influenza vaccination has 
been shown to increase by 19.2% annually from 2010-2017, where influenza 
vaccination within a pediatrician’s office decreased by 0.9% (19).  Particularly in the 5 
to 12 year old age group and 13-17-year old age group, these increases in pharmacist-




and overall increases in influenza vaccination rates (18), is contributing partially to 
increased vaccination.  
Considering the aforementioned findings, this study showed that pharmacists 
may have been providing additional influenza immunizations to children, who would 
not have otherwise been vaccinated, which therefore resulted in a decrease in 
transmission and diagnosis of the influenza virus in children.  A Canadian survey 
study among adults from 2013 showed that 25% of adult patients that were vaccinated 
by pharmacists were not yearly influenza vaccine recipients, 28% reported that if 
pharmacist-administered vaccination was not available they would not have received 
the influenza vaccination, and 99% would recommend being vaccinated by a 
pharmacist to their family and friends (20).   
The cumulative proportion of children vaccinated within a pharmacy for all 
states is very low; 5.2%, as well as state-level proportions of most comorbidities and 
some healthcare utilization.  This may attribute to the low numbers of comorbidities 
included in the multivariate model.  It would be interesting to run a similar model in 
adults, as adults are known to use pharmacies as places of vaccination more 
frequently, around 28% (7) and are more likely to present with comorbidities.  State-
level variations may change based on geographical differences and patient 
preferences, rather than corresponding minimum age restrictions. 
The burden of the influenza virus and disease among children is considerable 
(21, 22) and the influenza vaccine is recommended by the Centers for Disease Control 
and Prevention (CDC) and the Advisory Committee on Immunization Practices 




the influenza disease and influenza-related complications (28-30).  During the 2016-
2017 influenza season, 8.8 million symptomatic illnesses, 5 million medical visits, 
over 34,000 hospitalizations, and over 250 deaths were estimated among children less 
than 18 years old in the United States (31).  Approximately 10%-15% of children 
infected with influenza will need medical care and children less than 2 are at higher 
risk for hospitalization (22).  The influenza virus is also responsible for a tremendous 
economic burden, including direct costs for healthcare visits and treatment, which can 
range from $114 for a pediatric outpatient visit to upwards of $7,300 for a pediatric 
hospitalization (32), as well as indirect costs of missed school and caregiver work due 
to illness.  Two years after the introduction of pharmacist-administered influenza 
immunization in Ontario, Canada during the 2013-2014 influenza season, the county 
observed an increase in immunization rate by about 3% of the total population, with 
pharmacists providing influenza vaccines to both new patients and patients who may 
have previously been vaccinated elsewhere, resulting in a potential savings of $2.3 
million in direct and indirect influenza related costs (33). 
Children are not only at increased risk for severe infection and complications 
(34), but they are also well known for transmitting the disease throughout their 
households and communities (34-38) and vaccinating children has been shown to 
reduce illness among children, as well as reduce influenza illness and hospitalizations 
in older adults and the overall impact of influenza within the community (22, 35-39).  
Our study provides evidence that states with higher proportions of pharmacist-
administered pediatric influenza vaccination are associated with a lower cumulative 




population.  Pharmacists as vaccinators have the ability to decrease influenza 
diagnoses among children, and in turn, lesson some of the burden caused by the 
disease.  It would be interesting to evaluate if overall influenza diagnoses of both 
children and adults is affected by increased utilization of pharmacists as vaccinators. 
Recently, pharmacists have been granted vaccination authority in all states to 
children between the ages of 3 and 18 under the PREP Act to administer any FDA 
authorized vaccine (6).  Because of this, it is likely that children will be using 
pharmacists more as vaccinators for routine childhood vaccines, in addition to 
influenza vaccine, mainly as routine preventative care pediatrician visits may still be 
disrupted (40).  Our study proves that pharmacist-administered pediatric influenza 
vaccination is an effective way to decrease the number of influenza diagnoses.  We 
expect pharmacist-administered vaccination for other routine childhood vaccines will 
decrease infection rates for other vaccine preventable diseases as well.  This will be a 
critical step toward combating the major decline in routine pediatric vaccinations 
observed predominantly in the beginning of the COVID-19 pandemic. 
Limitations 
There are several limitations from the dataset used, a single commercially 
insured population within the United States, which does not represent the approximate 
30 million children with Medicaid (41).  We have assumed that influenza vaccination 
claims, categorization of provider setting, and claims of the clinical comorbidities of 
interest are accurately and consistently coded in the claims database.  Only the first 
influenza vaccine in each season was included and it is possible a different provider 




demographics and clinical characteristics at the state-level were evaluated from data 
available from the database.  Other confounders, body mass index, income, and health 
literacy could not be assessed.  One major potential confounder, race, was not 
available in our database and therefore was not included as a potential confounder, 
potentially influencing both pharmacist-administered pediatric influenza vaccination 
and influenza diagnoses. 
Additionally, it is possible to treat influenza at home with over the counter 
medications, without seeking medical attention for diagnosis.  These cases of 
influenza would not have an associated diagnosis and therefore not be captured using 
this study design.  Contracting influenza virus can potentially be avoided with 
infection control measures, such as proper hand hygiene and avoiding exposure to the 
virus (29), which was an uncontrollable covariate in this study.  Influenza peaks can 
also be affected by environmental factors, such as temperature and precipitation, that 
vary by state and were not considered (42).   
Cumulative incidence influenza diagnoses as well as individual demographic 
and comorbidity data were aggregated and reported at the state-level.  Due to the 
ecologic study design, this study is subject to confounding by group, where each state 
may have a different rate of disease regardless of vaccination status (43).  Ecological 
fallacy may also present bias of interpretation, which is when data from groups, in this 
case different states, is interpreted at an individual level (44).  However, this study is 
designed to evaluate each state and the age restrictions and vaccination rates rather 




regression model used in this study assumes that the relationship between influenza 

























We observed a significant decrease in influenza diagnoses among states with 
higher proportions of children vaccinated by a pharmacist.  We also observed, from 
previous studies, that the rate of pharmacist-administered influenza has been 
increasing in recent years (19).  These increases in pharmacist-administered pediatric 
influenza vaccination are likely contributing to increased influenza vaccination and 
decreased influenza diagnoses for all children. Pharmacists primarily administer 
influenza vaccines to children of older age groups (11, 19), where increases in 
utilization over the past decade have been observed (18).  Decreasing influenza 
diagnoses through pharmacist-administered pediatric influenza vaccination can help 
decrease the significant burden of influenza in children and throughout communities 
(35, 36, 39).  During the current COVID-19 pandemic, pharmacists will likely be 
vaccinating more children of all age groups for routine childhood vaccines as well as 
influenza and COVID-19 vaccines when they become available (6).  We presume this 
expanded access to vaccination by pharmacists will decrease infection rates for other 
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4.8 TABLES AND FIGURES 
Table 1. State-level pediatric influenza vaccination rates, pharmacist administered 




an influenza vaccine 










diagnoses (of those 
vaccinated) (%) 
Alaska (AK) 14.1 3.3 0 
Alabama (AL) 26.9 6.8 4.2 
Arkansas (AR) 36.1 8.8 2.4 
Arizona (AZ) 25.4 9.1 1.1 
California (CA) 31.5 4.5 0.7 
Colorado (CO) 40.5 9.4 1.4 
Connecticut (CT) 50.1 0.1 3.8 
District of Columbia (DC) 44.5 1.5 1.8 
Delaware (DE) 37.3 7.2 0.9 
Florida (FL) 24.4 0.3 2.9 
Georgia (GA) 28.6 4.9 3.7 
Hawaii (HI) 30.3 0 4.3 
Iowa (IA) 36.3 6.3 1.8 
Idaho (ID) 18.2 3.3 0.2 
Illinois (IL) 30.8 5.3 2.0 




Kansas (KS) 33.0 7.9 1.9 
Kentucky (KY) 32.0 3.8 2.3 
Louisiana (LA) 26.6 9.1 4.7 
Massachusetts (MA) 47.6 0.1 2.0 
Maryland (MD) 40.3 5.6 3.3 
Maine (ME) 26.8 8.6 0.3 
Michigan (MI) 29.9 8.7 1.9 
Minnesota (MN) 43.2 0.8 1.3 
Missouri (MO) 32.5 5.7 2.3 
Mississippi (MS) 17.8 10.9 4.6 
Montana (MT) 23.6 3.5 1.0 
North Carolina (NC) 37.9 3.2 4.5 
North Dakota (ND) 37.7 0.1 1.5 
Nebraska (NE) 45.0 8.4 1.3 
New Hampshire (NH) 39.9 6.0 1.8 
New Jersey (NJ) 50.0 2.0 4.5 
New Mexico (NM) 20.8 10.6 1.3 
Nevada (NV) 18.1 10.2 0.6 
New York (NY) 46.7 0.1 4.8 
Ohio (OH) 33.3 5.4 1.5 
Oklahoma (OK) 27.8 9.4 5.1 
Oregon (OR) 39.3 3.4 0.6 




Rhode Island (RI) 52.6 0.1 2.0 
South Carolina (SC) 26.9 3.5 5.2 
South Dakota (SD) 42.6 0 3.9 
Tennessee (TN) 30.2 8.5 3.6 
Texas (TX) 34.9 7.8 3.7 
Utah (UT) 34.6 6.3 0.6 
Virginia (VA) 40.6 8.2 4.4 
Vermont (VT) 41.5 2.0 0 
Washington (WA) 26.6 28.4 1.2 
Wisconsin (WI) 34.9 5.0 0.7 
West Virginia (WV) 25.0 1.6 3.4 
Wyoming (WY) 18.8 0 2.7 
Mean ± standard 
deviation 
33.4% ± 9.3% 5.4% ± 4.7% 2.3% ± 1.5% 

























-0.06 1.000   -6.1899 0.0369 
Age Group       
6 months to 4 years Ref Ref Ref 





13 to 17 years old 6.53 5.87 3.73 0.2189 
Region       






South 0.90 0.98 0.07 0.7676 





Pharmacist Authorization Model Age Restriction     
Does not allow, minimum age 18 Ref Ref Ref 





     Min 2 to 4 years old -0.10 1.93 0.79 0.2020 
     Min 5-12 years old, AA 0.45 1.38 0.27 0.3150 
     Min 5-12 years old 0.07 0.74 0.38 0.1466 
     Min 13-17 years old, AA 0.85 1.42 0.74 0.0609 
     Min 13-17 years old 1.01 -0.16 0.19 0.5767 
Healthcare Utilization and Common Pediatric Conditions     
Routine child health exam/Follow up 8.16 0.0006 -5.79 0.0610 10.20 <0.0001 
Fever 23.23 <0.0001 -5.13 0.5071 16.00 0.0003 
Prophylactic vaccination -7.67 0.0364 -10.56 0.0180 -8.37 0.0053 
Other Less Common Pediatric Conditions      
Chronic pulmonary disease (COPD)  123.82 <0.0001 -70.56 0.0629 70.58 0.0087 
 





Figure 1. Study Period Timeline   
 
 
Index Date – Influenza Vaccination Date 





Follow Up Period  
Influenza-related diagnosis 
Day 15 through June 30, 2017 
Exclusion Assessment 
Window 
(allow 14 days for 
immune response) 
Days [0, 14] 
Inclusion Assessment Window 
Pediatric Patients  
< 18 years of age 
Covariate Assessment Window 
Baseline conditions and demographics 
Days [-365, -1] Previous Flu Vaccine 




Supplemental Table 1. International Classification of Diseases Version 10 (ICD-10) 
codes for healthcare utilization and common pediatric diagnoses  
Condition (33) ICD 10 
Routine child health examination or 
Follow-up examination  
Z00.121, Z00.129 
Z09 
Acute upper respiratory infection J06.9 
Otitis media 
H65.01 - H65.06, H65.21 - H65.23, 
H65.111 - H65.116, H65.411 - 
H65.413, H66.001 - H66.003,  
H66.011 - H66.013, H66.004 - 
H66.006, H66.014 - H66.016, H66.11 
- H66.13, H66.21 - H66.23 
Acute pharyngitis J02.9 
Allergic rhinitis J30.1, J30.89, J30.9 
Sinusitis J32.0 - J32.4, J32.8, J32.9 
Dermatitis 
L23.0 - L23.2, L23.4 - L23.7, L23.81, 
L23.89, L23.9, L24.0 - L24.3, L24.5 - 
L24.7, L24.81, L24.89 
Attention-deficit/hyperactivity disorder F90.0, F90.1, F90.2, F90.8 
Cough R05 
Streptococcal sore throat J02.0 
Bronchitis J20.5, J20.6, J20.9 




B30.1,  B30.9 
Esophageal reflux K21.0, K21.9, P78.83 
Influenza  
J09X1, J09X2, J09X3, J09X9, J10.1, 
J10.2, J10.00, J10.01, J10.08, J10.81, 
J10.82, J10.83, J10.89, J11.1, J11.2, 
J11.00, J11.08, J11.81, J11.82, J11.83, 
J11.89 
Gastroenteritis/colitis K52.9 
Fever R50.83, R50.9 
Constipation, unspecified K59.00 
Prophylactic vaccination Z23 
Abdominal pain 
R10.13, R10.83, R10.84, R10.0, 
R10.31 - R10.33,  
R10.11, R10.12 
Viral diseases B33.8, B34.9 
Pneumonia J12.9, J18.0, J18.1, J18.8, J18.9 
Urinary tract infection, cystitis (34) 
N30.00, N30.01, N30.10, N30.11, 
N30.20, N30.21, N30.30, N30.31, 
N30.40, N30.41, N30.80, N30.81, 




Supplemental Table 2. International Classification of Diseases Version 10 (ICD-10) 
codes for underlying health conditions which increase the risk of severe influenza 
infection 
Condition ICD 10 
Blood disorders (27, 35, 36)       
     Hemoglobinopathy D58.2 
     Sickle cell anemia 
D57.00 – D57.02, D57.1, 
D57.20,  D57.211, D57.212, 
D57.219, D577.3, D57.40, 
D57.411, D57.412, D57.419, 
D57.80, D57.811, D57.812, 
D57.819 
     Thalassemia major D56.5, D56.8, D56.9 
Cardiac disease (27, 35, 36)  
     Atherosclerotic heart disease 
I25.10, I25.110, I25.111, 
I25.118, I25.119 
     Congenital heart disease 
Q20.8, Q20.9, Q21.8, Q21.9 , 
Q24.6, Q24.8, Q24.9 
     Coronary artery disease 
I25.750, I25.751, I25.758, 
I25.759, I25.811, I25.82 
Cognitive disorders (28, 36)  
     Intellectual disability F70, F71, F72, F73, F78, F79 




F80.81, F80.82, F80.89, F80.9, 
F82, F88, F89 
     Spinal cord injury 
G32.0, G95.11, G95.89, G95.9, 
Q06.8, Q06.9 
Hepatic conditions (36)  
     Chronic liver disease with cirrhosis 
K74.3, K74.4, K74.5, K74.60, 
K74.69 
Immunocompromised conditions (27, 35, 36)  
     HIV/AIDS B20 
     Cancer C00.0-C96.9 
     Chemotherapy Z51.0, Z51.11, Z51.12, 
     Chronic corticosteroid therapy Z79.52, Z92.241 
Metabolic/Endocrine conditions (27, 36, 37)  
     Diabetes (Type 1)  
     Diabetes (Type 2)  
E10.65, E10.9 
E11.65, E11.9 
Neurologic conditions (35, 36)  
     Cerebral palsy 
G80.3, G80.0, G80.1, G80.2, 
G80.4, G80.8, G80.9 
     Muscular dystrophy G71.0, G71.11 
     Neuromuscular disease 
 
M41.40, M41.41, M41.42, 
M41.43, M41.44, M41.45, 
M41.46, M4147 





Obesity (27, 36) 
E66.01, E66.09, E66.1, E66.2, 
E66.8, E66.9, Z68.54 
Respiratory disease (27, 35, 36)             
     Asthma 
 
J45.20, J45.21, J45.22, J45.30, 
J45.31, J45.32, J45.40, J45.41, 
J45.42, J45.50, J45.51, J45.52, 
J45.990, J45.901, J45.902, 
J45.909, J45.991, J45.998 
     Chronic lung disease 
J68.4, J70.1, J70.3, J84.848, 
J84.89, J84.9 
     Chronic obstructive pulmonary disease  J40, J41.0, J41.1, J41.8, J42 
     Cystic fibrosis 
E84.0, E84.11, E84.19, E84.8, 
E84.9 
     Pediatric emphysema J43.0, J43.1, J43.2, J43.8, J43.9,  
     Renal disease (27, 36) 
N01.0, N01.1, N01.2, N01.3, 
N01.4, N01.5, N01.6, N01.7, 
N01.8, N01.9, N03.0, N03.1, 
N03.2, N03.3, N03.4, N03.5, 
N03.6, N03.7, N03.8, N03.9, 
N04.0, N04.1, N04.2, N04.3, 
N04.4, N04.5, N04.6, N04.7, 




N07.2, N07.3, N07.4, N07.5, 













9952 PROPH VACCINATION AGAINST FLU 
90470 H1N1 IMMUNIZATION, IM AND INTRANASAL 
90630 FLU VACC IIV4 NO PRESERV ID 
90653 IIV ADJUVANT VACCINE IM 
90654 FLU VACC IIV3 NO PRESERV ID 
90655 IIV3 VACC NO PRSV 0.25 ML IM 
90656 IIV3 VACC NO PRSV 0.5 ML IM 
90657 IIV3 VACCINE SPLT 0.25 ML IM 
90658 IIV3 VACCINE SPLT 0.5 ML IM 
90659 FLU VACCINE WHOLE IM 
90660 LAIV3 VACCINE INTRANASAL 
90661 CCIIV3 VAC NO PRSV 0.5 ML IM 
90662 IIV NO PRSV INCREASED AG IM 
90663 FLU VACC PANDEMIC H1N1 
90664 LAIV VACC PANDEMIC INTRANASAL 
90666 FLU VAC PANDEM PRSRV FREE IM 
90667 IIV VACC PANDEMIC ADJUVT IM 




90672 LAIV4 VACCINE INTRANASAL 
90673 RIV3 VACCINE NO PRESERV IM 
90674 CCIV4 VAC NO PRSV 0.5 ML IM 
90682 RIV4 VACC RECOMBINANT DNA PRSRV ANTIBIO FREE IM 
90685 IIV4 VACC NO PRSV 0.25 ML IM 
90686 IIV4 VACC NO PRSV 0.5 ML IM 
90687 IIV4 VACCINE SPLT 0.25 ML IM 
90688 IIV4 VACCINE SPLT 0.5 ML IM 
90689 IIV4 VACC INACTIVATED, ADJUVN, PRSV FREE 0.25 ML IM  
90724 INFLUENZA IMMUNIZATION 
90737 INFLUENZA B IMMUNIZATION 
90756 IIV4 VACC INACTIVATED ABX FREE 0.5 ML 
3E01340 INTRO FLU VACCINE SUBQ TISSUE PC 
4035F INFLUENZA IMM REC 
4037F INFLUENZA IMM ORDER/ADMIN 
G0008 ADMINISTRATION INFLUENZA VIRUS VACC 
G8108 PT DOC RECV FLU VACC DUR FLU SEASON 
G9141 INFLUENZA A H1N1 IMMUNIZATION ADMIN 
G9142 INFLUENZA A H1N1 VACCINE ANY ROUTE 
Q0034 INFLUENZA VACCI; MEDICAR 
Q2033 INF VACC RECOMB HEMAGGLUTININ AG IM 
Q2034 FLU VIRUS VAC SPLIT VRS IM AGRIFLU 




Q2036 FLU VACC SPLIT 3 YR & > IM FLULAVAL 
Q2037 FLU VACC SPLIT 3 YR & > IM FLUVIRIN 
Q2038 FLU VACC SPLIT 3 YRS & > IM FLUZONE 
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